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Abstract
The prototypic receptor-like protein tyrosine phosphatase CD45 is proteolytically 
cleaved in human monocytes and granulocytes upon activation via zymosan or 
PMA. The cytoplasmic tail of ct-CD45 (ct-CD45) is released via activation-
induced cell death. Ct-CD45 acts as a cytokine-like factor on human T cells, 
thereby, potently reducing proliferation and cytokine production leading to an 
anergy-like state in T cells.
The aim of this work is to elucidate the molecular mechanisms governing ct-
CD45-induced T cell anergy. A potential receptor candidate for ct-CD45 on T 
cells was identified to be PRAT4A. Here, we demonstrate that binding of ct-
CD45 to a murine cell line transfected with human PRAT4A can be blocked by 
an antibody against PRAT4A. Induction of the anergic state is accompanied by 
an inhibition of T cell blast formation suggesting an early cell cycle arrest. 
Microarray analysis of T cells activated in the presence of ct-CD45 indicated 
upregulation of two factors not known to be associated with anergy before -
Schlafen family member 12 (SLFN12) and Krueppel-like factor 2 (KLF2). While 
KLF2 is a transcription factor implicated in the maintenance of T cell 
quiescence, little is known about SLFN12. SLFN12 is a primate-specific factor 
which belongs to a gene family that is involved in thymocyte development and 
cellular growth regulation. The expression of both factors was confirmed and 
analyzed via quantitative real-time PCR identifying SLFN12 as a putative 
anergy factor. IL-2 strongly reduced SLFN12 mRNA whereas KLF2 expression 
was barely changed. Furthermore only SLFN12 showed early induction in ct-
CD45-treated T cells. Transfection of a SLFN12 siRNA could partially restore 
proliferation of anergic cells. Expression profiling of cell cycle-associated factors 
supported an early cell cycle arrest as cyclin D1 showed impaired induction 
while other factors were unaltered. 
Taken together, these results demonstrate that ct-CD45 induces anergy via 
PRAT4A subsequently leading to the induction of SLFN12. Inhibition of cyclin 
D1 results in an early cell cycle arrest characterized by reduced lymphoblast 
formation resembling cellular quiescence. Thus, our data supports a novel 
functional state for T cells.
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Zusammenfassung
Die klassische Proteintyrosinphosphatase CD45 kann in humanen Monozyten 
und Granulozyten bei Aktivierung durch Zymosan oder PMA proteolytisch 
gespalten werden. Die Freisetzung der cytoplasmatischen Domäne von CD45 
(ct-CD45) erfolgt durch aktivierungsinduzierten Zelltod. Diese Domäne bindet 
als löslicher Faktor an humane T-Zellen und reduziert Proliferation und 
Zytokinsekretion was zur Ausbildung eines anergieähnlichen Zustandes führt.
Das Ziel der vorliegenden Arbeit ist es die molekularen Mechanismen, welche 
hinter der von ct-CD45 verursachten Anergie stehen, zu analysieren. Mit 
PRAT4A hat unser Labor in einer früheren Studie einen Rezeptorkandidaten für 
ct-CD45 identifiziert. In dieser Studie demonstrieren wir, dass die Bindung von 
ct-CD45 an eine PRAT4A-überexprimierende Zelllinie durch einen Antikörper 
gegen PRAT4A unterbunden werden kann.
Es wird gezeigt, dass die Induzierung dieses Zustandes von einer verminderten 
Bildung von Lymphoblasten begleitet wird, was auf einen frühen 
Zellzyklusarrest hindeutet. Microarray-Analyse von humanen T-Zellen die in der 
Gegenwart von ct-CD45 aktiviert wurden, zeigte die Überexpression zweier 
Faktoren – Krüppel-like factor 2 (KLF2) und Schlafen family member 12 
(SLFN12). Während KLF2 ein bekannter, mit der Regulation von T-
Zellquieszenz assoziierter Faktor ist, weiß man wenig über SLFN12. Dieser 
Faktor wird nur in Primaten exprimiert und gehört einer Genfamilie an, die mit 
Thymozytenentwicklung und zellulärer Wachstumsregulierung in Verbindung 
gebracht wird. Diese Studie bestätigt die Überexpression von beiden Faktoren 
mittels quantitativer Realtime-PCR und identifiziert SLFN12 als möglichen 
Anergiefaktor. IL-2 reduzierte die Expression von SLFN12 mRNA wogegen 
KLF2 kaum reguliert wurde. SLFN12 wurde zudem bereits kurz nach 
Aktivierung in der Präsenz von ct-CD45 hochreguliert. Die Transfektion einer 
SLFN12 siRNA verbesserte die Proliferation von T-Zellen die in der Gegenwart 
von ct-CD45 aktiviert wurden. Die Expressionsmuster von Zellzyklusfaktoren 
unterstützen einen frühen Zellzyklusarrest durch ct-CD45, da sich die 
Expression von Zyklin D1, nicht aber von anderen Faktoren verringert zeigte. 
Zusammenfassend zeigt diese Arbeit, dass ct-CD45 über die Bindung an 
PRAT4A T-Zellanergie induziert und zu einer Hochregulierung von SLFN12 
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führt. Die spezifische Inhibierung von Zyklin D1 führt zu einem frühen 
Zellzyklusarrest, der sich in einer verringerten Bildung von Lymphoblasten 
manifestiert, welche morphologisch ruhenden Zellen ähnlich sind. Unsere Daten 
unterstützen daher einen neuen funktionalen Differenzierungszustand von T-
Lymphozyten.
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1. Introduction
The central role of the immune system lies in the prevention of infection and in 
the containment and subsequent eradication of established infections [1]. In 
order to achieve this, the immune system relies on two major defence 
mechanisms consisting of innate and adaptive immunity. 
1.1. Innate immunity
Innate immunity conveys the immediate and the early immune response 
towards infection [2]. Innate immune defence mechanisms include physical 
barriers against pathogenic entry such as epithelia, molecular components like 
the serum proteins of the complement system and cellular effectors including
phagocytes (i.e. neutrophil granulocytes and macrophages), professional 
antigen-presenting cells like dendritic cells (DCs) and natural killer (NK) cells
[1].
The pathogen specificity of the innate immune system is based on the 
recognition of conserved molecular structures which are common to different 
classes of microbes, but are not found on cells of the host. These conserved 
structures, which are also termed pathogen-associated molecular patterns 
(PAMPs) are bound by germline-encoded pattern recognition receptors (PRRs)
[1]. Among these receptors is, for instance, the mannose receptor on 
macrophages which recognizes terminal mannose residues, a typical feature of 
many microbial glycoproteins. Triggering the mannose receptor also mediates 
phagocytosis and subsequent degradation of pathogens within 
phagolysosomes [1].
Pattern recognition receptors also comprise the Toll-like receptor (TLR) family. 
While there are 10 TLR family members in humans, 12 functional TLRs have 
been identified in mice [3]. TLRs are expressed intracellularly as well as on the 
cell surface depending on the type of ligand being bound. For instance, TLR-3, 
TLR-7, TLR-8 and TLR-9, all of them binding nucleic acids, are localized in
intracellular vesicles, including the endoplasmic reticulum (ER), endosomes, 
lysosomes or endolysosomes [3]. Their intracellular location is crucial to enable 
the recognition, for example, of viral nucleic acids but also to prevent contact to 
self nucleic acids which would potentially initiate autoimmune disease [3].
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Conversely, TLR-1, TLR-2, TLR-4, TLR-5 and TLR-6 which recognize microbial 
membrane or cell wall components are located on the cell surface [2,3]. For 
example, TLR-4 (together with MD-2 and CD14) recognizes lipopolysaccharide
(LPS), a cell wall component of gram-negative bacteria, while the TLR-2/TLR-6 
heterodimer binds bacterial lipoproteins, lipoarabinomannan, peptidoglycan and
zymosan, a component of yeast [2].
TLRs as well as other PRRs are widely distributed on immune cells and play an 
important role in their activation. DCs also require signalling through TLRs in 
order to fully mature and acquire the ability to migrate and present antigen 
taken up in the periphery to naïve T cells in the lymph nodes. Thus, they are 
important initiators of adaptive immune responses [2].
1.2. Adaptive immunity
Unlike innate immunity the specificity of the adaptive immune system relies on 
the recognition of distinct antigenic structures rather than conserved microbial 
patterns [1]. While PAMPs are conserved macromolecular structures, the 
antigens recognized by adaptive immune cells are highly specific enabling the 
detection of non-microbial antigens. The variety of the receptors of adaptive 
immunity is based on the somatic recombination of gene segments which leads 
to a much greater diversity than can be achieved for innate immune receptors. 
Adaptive immune receptors are distributed on lymphocytes, i.e. B and T cells 
which express B and T cell receptors, respectively [1]. A distinct feature of these 
receptors is their clonal distribution, only a few clones of B or T lymphocytes in 
the entire population are specific for a certain epitope of an antigen. Upon 
recognition of their cognate antigen, antigen-specific clones readily expand. 
Some of the clones persist as long-lived memory cells initiating even stronger 
responses upon reencounter with the antigen. Immunological memory is thus a 
hallmark of adaptive immunity [1].
B cell receptors are membrane-bound antibodies or immunoglobulins (Ig) which 
recognize either conformational or linear epitopes of macromolecules, like 
proteins, lipids or carbohydrates. Antigen-binding leads to the activation of a 
naïve B cell and differentiation to an antibody-secreting plasma cell. Secreted 
antibodies are found in the blood or are at mucosal sites binding and 
neutralizing extracellular pathogens or toxins. This type of immunity is termed 
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humoral immunity. Additionally, antibodies also mediate cellular effector 
functions carried out by innate immune cells expressing receptors for the Fc-
part of antibodies. These functions include, for instance, phagocytosis of 
opsonized microbes by phagocytes or complement activation via the classical 
pathway. These effector functions are specific for antibody isotypes which are 
secreted as a result of immunoglobulin class-switch [1].
Unlike B cells T lymphocytes are mediators of cell-mediated immunity towards 
intracellular pathogens such as viruses or intracellular bacteria. Different to the 
B cell receptor the T cell receptor (TCR) only recognizes processed forms of 
protein antigens which are presented by the body’s cells on major 
histocompatibility complex (MHC) molecules [2].
1.3. T cell development
T cells arise from hematopoietic progenitors in the bone marrow which enter the 
thymus for final differentiation [4]. T cell development within the thymus consists 
of a series of signalling events which decide about the cellular fate of 
thymocytes and lineage commitment into either CD4 or CD8 co-receptor-
bearing T lymphocytes. Thymocytes are initially generated via the interaction 
between haematopoietic stem cells and thymic stromal cells [5]. In this early 
phase the cells still-lack CD4 or CD8 expression and have to traverse a series 
of distinct double-negative stages during? ?????? ???? ?-chain of the TCR 
undergoes rearrangement of its several variable (V), diversity (D) and joining (J) 
gene segments until a pre-TCR is assembled from?????????????????-chain and 
?? ?????????? ?-chain [2,5]. ??? ????? ??? ?-chain rearrangement is completed T 
cells start to express CD4 and the CD8?? heterodimer. At this double-positive 
stage the ???? ?-chain rearranges its V and J segments leading to the 
assembly of the fully rearranged TCR. [2, 104] Newly assembled TCRs are then 
selected via their avidity of binding of self-peptide:MHC complexes. Very weak 
to no interaction leads to “death by neglect”. Conversely, a subsequent strong 
interaction induces cell death via “negative selection”. Only intermediate
interaction with self-peptide:MHC complexes leads to “positive selection” of 
thymocytes which become mature T cells [104]. Depending on the class of 
MHC-molecules recognized thymocytes either retain the expression of the CD4 
or the CD8 co-receptor which gives rise to the two main T cell lineages. 
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1.4. Morphological and functional plasticity of T cell differentiation 
Triggering of the TCR sets the stage for the functional differentiation of a T cell. 
Basic T cell differentiation states are accompanied by characteristic cellular 
phenotypes (Table 1). Quiescent lymphocytes are small with reduced 
metabolism but readily proliferate when receiving signals through the TCR [58].
TCR engagement in the absence of costimulation typically induces a 
tolerogenic or anergic T cell phenotype while full stimulation results in the 
differentiation into various effector cell subsets [102]. 
phenotype
quiescent 
lymphocytes
activated 
lymphocytes
anergic
lymphocytes
cell size small large large
rate of protein synthesis low high low
response to activation proliferation
expansion or 
apoptosis
none or apoptosis
sensitivity to FasL-
dependent apoptosis low high high
Table1: Morphological and functional characteristics of basic T lymphocyte 
differentiation states. Adapted from Yusuf and Fruman [58].
Activation results in dramatic increases in cellular size which is found in both 
fully activated as well as in anergic lymphocytes [58]. A key difference between 
these two functional states lies in their responsiveness to subsequent 
stimulation. While activated T cells typically show further expansion towards 
TCR stimulation anergic lymphocytes are hyporesponsive which is 
accompanied by reductions in cellular protein synthesis similar to quiescent T 
cells [58]. The anergic phenotype might also be accompanied by the 
acquirement of regulatory T cell (Treg) characteristics [45]. T cell activation also 
renders T cell susceptible to activation-induced cell death and to apoptosis 
mediated via Fas ligand [58] which might be important for the contraction of 
immune responses and prevention of autoimmunity [103].
Differentiation of activated T lymphocytes into effector subsets depends on the 
cytokine environment as well as on the strength of the TCR stimulus [102]. 
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Effector subsets of CD4+ T cells are generated and reinforced by a distinct 
milieu. However, this differentiation is not always a terminal fate and can be 
destabilized by changing conditions thus favoring differentiation towards 
another subset [107].
T cell differentiation and its plasticity are actively regulated on the molecular 
level involving antagonizing transcriptional programs which may be induced by 
external factors such as cytokines. Stability of a T cell differentiation state may 
also depend on transcriptional curcuits favoring its own expression via positive 
feedback loops while repressing another fate [107]. Examples for such 
processes are the mutual antagonism of the transcription factors T-bet 
regulating the development of Th1 cells and GATA-3 favouring Th2 cell 
development [107]. Highly stable states might depend on repeated cell divisions 
in order to be reversed such as clonal anergy which requires the T cell growth 
factor IL-2 to return to a state of full T cell activation [45]. Molecular factors and 
pathways involved in the functional differentiation of T lymphocytes are 
discussed in more detail in the following sections.
1.5. T cell lineages
CD4+ T cells
CD4+ T helper (Th) cells are crucial for the initiation and modulation of adaptive 
immunity [6]. Th cells recognize antigens processed and presented by antigen-
presenting cells (APCs) on MHC class II molecules [2]. The main effector 
function of activated CD4+ T cells lies in cytokine and chemokine production [6]. 
Th cells may give help to primary CD8+ T cell responses. However, they have 
been shown to be essential for the generation of memory and initiation of 
secondary responses [14]. Similarly, there is a need for CD4+ T cells for the 
clonal selection of germinal center B cells to establish B cell memory and the 
regulation of antibody class switch as well as affinity maturation [6,9].
CD4+ T cell comprise a heterogeneous population with distinct functions [6]. 
Differentiation into subsets is regulated via the cytokine microenvironment but 
also depends on the strength of the TCR interaction with its cognate antigen [7].
Lineage choice is associated with the induction of a distinct transcriptional 
programme [6,7].
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Differentiation into the Th1 lineage is achieved via the cytokines IL-12 and IFN-
??? ???? ??????? ??? ???? ?????? ????????? ????????? ??? ?????? ?????? ???? ????? ??? ????
activation of macrophage-mediated phagocytosis of pathogens. Transcription 
factors expressed by these cells are STAT4, STAT1 and T-bet. [2, 7]. 
The Th2 subset requires IL-4 for its differentiation which is governed by the 
activity of GATA-3 and STAT6 transcription factors. Its physiological role lies in 
immunity against helminthic worms and other extracellular parasites by
promoting antibody class switch especially to IgE. Th2 cytokines include IL-4, 
IL-5 and IL-13 [2, 7].
Immunity against extracellular bacteria and fungi at mucosal sites is mediated 
via Th17 cells which are producers of IL-17A, IL-17F and IL-22 [7]. These 
cytokines act proinflammatory by inducing cytokine production of epithelial, 
endothelial and fibroblast cells and help in neutrophil recruitment [2]. 
Polarization towards Th17 depends on signalling via TGF-?????-6, IL-21 and IL-
23, ultimately leading to activation of the lineage-specific transcription factor 
(????????7]. However, interspecies differences have been found between mice 
and human Th17 cells in several aspects. In contrast to mice, the human Th17 
cell lineage not only expresses (?????? but also T-bet as central transcription 
factors. Furthermore these cells show the propensity to secret IFN-? besides IL-
17A in the presence of IL-12 suggesting a close relationship to Th1 cells. There 
is also indication for a different origin of human Th17 cells from CD161+
precursors with constitutive (?????? and IL-23R expression [8].
Another possible T helper cell subset was discovered recently. Th22 cells were 
found to produce IL-22 in the absence of other lineage-specific cytokines [105]. 
Similar to IL-17, IL-22 exerts its action on non-hematopoietic cells rather than 
immune cells. IL-22 production seems to be linked to inflammatory states of the 
skin during which Th22 cells probably develop from the Th17 subset [105].
T follicular helper cells (Tfh) are a subset of CD4+ T cells which regulates 
antigen-specific B cell immunity (7,9). Tfh cells are located to B cell follicles 
through their expression of the chemokine receptor CXCR5 [9]. Their 
differentiation requires IL-6 and IL-21 leading to the expression of a specific 
transcriptional program including Bcl-6 and STAT-3 [9].
Another important T helper cell population are regulatory T cells. Tregs express
FOXP3, a transcription factor critical for regulatory T cell function. Two major 
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groups of regulatory T cells have been characterized depending on their site of 
induction [7]. While naturally occurring CD4+ CD25+ Tregs (nTregs) arise from the 
thymus [7], T regulatory cells can also be induced in the periphery via TGF-??
signalling (iTregs) leading to the expression of FOXP3 [7,10]. Both types of cells 
are assumed to play an essential role in peripheral immune tolerance in order to 
prevent autoimmunity [7] with their suppressive activity mainly relying on the 
action of TGF-? [11]. However, different to iTregs the suppressor activity of nTregs
seems to be blocked by IL-6 [11].
Another subset of CD4+ T cells are Natural killer T cells, although these cell 
type can also have a CD4-CD8- phenotype [106]. NKT cells are generated 
during thymic development of T cells at the double-positive stage via 
recognition of CD1d which is a non-classical class I antigen-presenting 
molecule for glycolipids [106]. Characteristic features of NKT cells are the 
expression of a TCR with limited ?-chain diversity while also having NK cell 
receptors. Interestingly, NKT cells seem to acquire a memory T cell phenotype 
already during thymic selection and produce both, Th1 and Th2 cytokines upon 
activation [106].
CD8+ T cells
Cytotoxic T lymphocytes (CTLs) are essential for the immune response against 
viruses. They express the CD8 co-receptor and thus recognize peptide:MHC 
class I complexes [1,2,12-14]. Antigen processing for display on MHC class I 
typically involves the uptake of cytosolic proteins into the endoplasmic reticulum 
(ER). However, CD8+ T cells can also be presented with extracellular antigens 
via a mechanism termed cross-presentation. Antigens derived from virus-
infected cells or tumor cells taken up via phagocytosis by an antigen-presenting 
cell can be translocated from the ER to the cytoplasm and thus be alternatively 
loaded on MHC class I molecules [2]. Cross-presentation is most efficiently 
performed by dendritic cells [15].
Upon activation in the lymph nodes via dendritic cells CTLs rapidly expand 
undergoing cell division every 4 to 6 hours [16]. During this phase they also gain 
effector functions and the capacity to migrate to reservoirs of infection [16,17].
The effector functions of CTLs mainly rely on their cytoxic or cytolytic activity
whereby target cells are killed upon recognition either via the release of lytic 
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granules containing perforins and granzymes or through the engagement of 
death receptors [17]. Perforins are calcium-dependent pore-forming proteins 
which are involved in the delivery of other granule contents, while granzymes 
are serin-proteases which cleave the pro-apoptotic proteins such as Bid leading 
to cytochrome c release and caspase-activation [18]. However, cell death can 
also be induced independent of granzymes. CTLs express ligands for receptors 
of the tumor necrosis factor (TNF) superfamily which are expressed on the 
target cells including Fas, TNFR1, TNFR2 or TRAIL-R [18]. The FasL-Fas 
interaction leads to the direct recruitment of pro-caspase 8 via adaptor 
molecules subsequently initiating apoptosis in a caspase-dependent fashion
[18].
1.6. T cell activation
The process of T cell activation is initiated in secondary lymphoid organs such 
as lymph nodes where naïve T lymphocytes search the surfaces of dendritic 
cells for specific peptide-MHC complexes [19]. Recognition of less than 10 
specific pMHC complexes has been found sufficient to induce long-lasting 
contacts between T cells and dendritic cells ranging between 6 and 18 hours
[19]. These contacts (“immunological synapses”) finally lead to the activation of 
the T cells which subsequently enter the cell cycle and differentiate into effector 
cells [19]
Central to this process is the ligation of the T cell receptor with its cognate
pMHC complex which determines antigen specificity and initiation of T cell 
activation. However, additional signals are needed for the full activation of T 
cells. Signaling through the TCR alone was not only found to be insufficient for 
activating T cells but also to result in a hyporesponsive state termed anergy
[20]. Thus, a two-signal-model was established. “Signal 1” refers to the 
engagement of the TCR, while “signal 2” implies the ligation of additional 
costimulatory molecules presented by antigen-presenting cells [20].
The immunological synapse
The term “immunological synapse” (IS) broadly refers to any functional structure 
formed between APC and T cell, although its original meaning was restricted to 
a characteristic “bull’s-eye” structure formed by concentric rings of molecules
Introduction
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[21]. The inner circle or central supramolecular activation cluster (cSMAC) 
consists of the TCR, the co-receptors (CD4 or CD8) as well as of receptors 
engaged during co-stimulation such as CD28 or CD2. The outer circle is termed
peripheral supramolecular activation cluster (pSMAC) containing integrins, 
especially LFA-1, which are important for cell-cell adhesion [19, 21]. Outside the 
pSMAC lies an area of active membrane movemement called distal 
supramolecular activation cluster (dSMAC) [19].
Initially, the function of the cSMAC was assumed to lie in the delivery of the 
activating signals. However, it was found that this central ring rather serves 
TCR internalization and degradation while active TCRs are mainly located 
within the pSMAC [19]. Thus, the function of the cSMAC might be linked to the 
regulation of long-term T cell responses. Besides T cell priming, the IS might 
also function in mediating the contact between activated CTLs and their target 
cells focussing the content of cytolytic granules on the target cell to avoid 
causing damage to bystander cells [19].
However, the bull’s-eye structure is not required per se to initiate T cell 
activation. Contact of T lymphocytes with dendritic cells is characterized by the 
establishment of multiple TCR clusters giving rise to multifocal immunological 
synapses resulting in efficient activation of the T cells [21].
TCR signal transduction
???????? ????????? ??? ??? ??? ???????? ??? ?????? ????? ???? ???????? ???? ??????????
signaling activity. TCR signal transduction requires the association with the CD3 
complex consisting of dimeric ??, ??? and ?? chains [22]. Binding of cognate 
pMHC complexes activates protein tyrosine kinases (PTKs) of the Src family 
which are associated either with the TCR or the co-receptors [22]. 
Upon activation, Src kinases such as Lck or Fyn phosphorylate immunoreceptor 
tyrosin-based activation motifs (ITAMs) within the CD3 chains which serve as 
recruitment domains for ZAP-70 kinase. ZAP-70 phosphorylation via Lck 
activates the former leading to further downstream signalling events [22]. 
Targets of ZAP-70 are the transmembrane adaptor protein LAT and the 
cytosolic SLP-76 which contains a Src homology 2 (SH2) domain. The two 
adaptors form the basis of a protein complex from which multiple signalling 
pathways originate [22]. Phoshorylation of LAT tyrosine residues via ZAP-70 
Introduction
22
leads to the recruitment of other proteins including phospholipase C?1 (PLC?1), 
phoshoinositide-3-kinase and the adaptor proteins Grb2 and Gads [22].
Activation of PLC?1 upon TCR ligation leads to the enzymatic hydrolysis of the 
membrane phosholipid phosphatidylinositol-4,5-bisphosphate (PIP(4,5)P2) into
phosphoinositol-1,4,5-trisphosphate (PIP3) and diacylglycerol (DAG) both 
serving as second messengers [22,23].
PIP3 binds to ion channel receptors of the endoplasmic reticulum (ER) which 
are permeable for Ca2+ thus initiating release of Ca2+ ions into the cytosol. Ca2+
released from the ER additionally stimulates the inflow of extracellular Ca2+ ions 
via Ca2+-dependent channels (CRAC) of the plasma membrane [22]. The 
increase in cytosolic Ca2+ leads to the activation of various Ca2+- and 
calmodulin-dependent transcription factors as well as signalling factors such as 
calcineurin, a serin/threonin phosphatase [22,24].
Fig. 1: Simplified scheme of TCR signalling pathways. Major components involved in the 
signal transduction upon TCR ligation and costimulation (not shown). Signalling results in the 
recruitment of transcription factors central to T cell function including ????? ???? ???? ??????
forms heterodimers with NFAT [22, 30]. Figure was adapted from Razzaq et al. [30].
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Calcineurin dephosphorylates members of the nuclear factor of activated T cells 
(NFAT) transcription factor family, namely NFAT1, NFAT3 and NFAT4 [24].
Dephosphorylation of N-terminal serine residues within NFAT proteins reveals a 
nuclear import sequence subsequently mediating their translocation to the 
nucleus [24]. Within the nucleus NFAT forms cooperative complexes with other 
transcription factors thus linking several signalling pathways [22,24]. These 
interactions depend on additional signals besides the one released via the TCR 
[22], for example, on the presence of IL-2 signalling [25]. One of these
interactions is the formation of NFAT/AP-1 complexes [22]. The transcription 
factor activator protein 1 (AP-1) is a dimeric protein consisting of either Fos-Jun 
heterodimers or Fos-Fos homodimers. The complex formed by NFAT/AP-1
combines the signals of the Ca2+/calcineurin and of the mitogen-activated 
protein kinase (MAPK) pathways [24]. Interaction of NFAT with AP-1 is 
important for the expression of genes regulating for T cell proliferation and 
effector function including IL-2, IFN-? and IL-4 [22, 24]. Conversely, NFAT 
activity without the action of AP-1 has been shown to result in T cell anergy [26].
DAG, the second product of PIP(4,5)P2 hydrolysis serves as the activator of two 
signalling pathways, namely the Ras-Raf-MAPK pathway and the PKC?
pathway [22]. Ras is a GTP-binding protein which is required for the activation 
of the serine/threonine MAPK kinase kinase (MAPKKK) Raf-1. Raf-1 
phosphorylates MAPK kinases (MAPKK) which themselves activate the MAP 
kinases (MAPK) Erk-1 and Erk-2. The latter activate the transcription factor Elk-
1 subsequently inducing the expression of AP-1 [22].
Protein kinase C? (PKC?) is activated by DAG via binding to its specific lipid-
binding domain which recruits the kinase to the plasma membrane [22]. PKC?
induces then the activation and nuclear translocation of the nuclear factor NF-
?B (NF-?B) by promoting the assembly of a complex of the adaptor proteins
CARMA1, Bcl-10 and MALT1 [27]. Serine phosphorylation of CARMA1 induces 
complex formation which subsequently activates the inhibitor of NF-?B kinase 
(IKK) complex. IKK then promotes degradation of inhibitor of NF-?B (I?B) which 
sequesters the transcription factor in the cytosol. NF-?B release results in its 
nuclear translocation [27]. NF-?B is a transcription factor essential for the 
function of immune cells. In lymphocytes, it regulates cell proliferation by 
induction of cell cycle-associated genes such as cyclin D1, cyclin D2 or c-Myc
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as well as cell survival by the upregulation of the anti-apoptotic genes Bcl-2 and 
BCL-XL [28]. NF-?B also regulates cytokine genes including the T cell growth 
factor IL-2 or pro-inflammatory IL-6. Another NF-?B target gene is the 
costimulatory molecule CD40 ligand (CD40L) [28].
T lymphocyte activation through TCR signalling is also associated with profound 
cytoskeletal changes which are necessary to mediate various tasks important 
for T cell function, including cell growth, migration, cell-cell adhesion to APCs as 
well as to endothelial cells and extravasation into tissues [29]. TCR stimulation 
induces the formation of receptor clustering and of immunological synapses 
given the presence of costimulation. These events require the linkage to the 
actin and myosin cytoskeleton which convey these dynamic changes. A key 
molecule for linking TCR signals to the cytoskeleton is the guanine nucleotide 
exchange factor Vav1 which is linked to the LAT signalosome via SLP-76. Vav1 
functions to activate the Rho-like GTPases cdc42, Rac and Rho which mediate 
cytoskeletal changes [29].
Signalling pathways originating from TCR stimulation are summarized in Fig. 1.
T cell costimulation
Costimulation serves as “signal 2” to TCR stimulation and is required for the full 
activation of T cells. Although soluble factors such as cytokines can augment T 
cell activation the term “costimulation” is typically restricted to the interaction of 
membrane-bound receptor-ligand pairs. Costimulation can promote both, 
activating as well as inhibitory pathways depending on the nature of the 
costimulatory molecule engaged [31]. 
The most intensively investigated costimulatory interaction is the one of the T 
cell receptor CD28 with its ligands of the B7 family. CD28 is a homodimeric 
glycoprotein which is linked via disulfide bonds. It spans the plasma membrane 
displaying type I transmembrane protein topology [20].
Human T cells do not uniformly express CD28. While about 80% of CD4+ T 
cells are positive for CD28, it can be detected on roughly half of all CD8+ T cells 
[20]. Signalling through CD28 has profound effects on the threshold of TCR 
triggering which is significantly lowered. The increased sensitivity also results in 
enhanced cytokine production, most importantly of IL-2 [20].
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CD28 engages with two ligands on APCs, namely B7-1 (CD80) and B7-2 
(CD86). However, these ligands interact with another receptor on T cells termed 
cytotoxic T lymphocyte associated antigen 4 (CTLA-4) which transduces 
inhibitory signals into T cells [31,32]. Although structurally similar, CTLA-4 has 
higher binding affinities for both ligands. The two receptors display differential
distribution on T cells. While CD28 is expressed on both, resting as well as 
activated cells, CTLA-4 is induced during the process of T cell activation [32] in 
order to prevent excessive T cell responses [31]. However, its expression is 
constitutive on Tregs [32]. Lack of CTLA-4 results in uncontrolled T cell activation 
and autoimmune disease [33].
CD28, CTLA-4 and their ligands CD80 and CD86 belong to the B7-CD28 
superfamily which is generally accepted as the major group of T cell 
costimulatory molecules [31]. Other members of this family include inducible 
costimulator (ICOS) and its ligand (ICOSL) which are associated with the 
differentiation of T helper cells, the production of Th lineage cytokines and the 
regulation of B cell responses [31] by promoting the induction of follicular T 
helper cells [33]. CD28 and ICOS were shown to act synergistically in T cell 
activation as only the absence of both pathways resulted in the loss of T cell 
effector function [34].
Another receptor-ligand interaction of the CD28-B7 superfamily is the one of 
programmed cell death 1 (PD1) with its ligands PD-L1 and PD-L2. Its primary
action is inhibitory, although an alternative activating function has been 
described in mice [31].
The Tumor necrosis factor receptor (TNFR) superfamily also contains several 
costimulatory molecules the most potent of which is the 4-1BB/4BBL interaction. 
Other important interactions within this family are the ones of OX40 with its 
ligand or of CD27 with CD70 [31]. 
Besides the two major pathways mentioned other costimulatory pathways exist 
including the interaction of members of the CD2 superfamily, integrins, 
tetraspanins or the TIM family [31]. 
Integrins comprise a large protein family which function as receptors as well as 
adhesion molecule??? ?????? ?????????? ??? ???????? ????? ??????????? ??? ?? ???? ?
subunits [35]. Integrin are expressed on cell surfaces typically in an inactive 
form. Signalling via other receptor such as the TCR is required to achieve an 
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active conformation which is dependent on linkage to the cytoskeleton [35] The 
main T cell integrin is lymphocyte-function associated antigen 1 (LFA-1) which 
interacts with intercellular adhesion molecule 1 (ICAM-1) [31,35] as well as with 
ICAM-2 and ICAM-3 [31]. This interaction functions on the one hand to promote 
arrest of T cells on endothelial surfaces inside blood vessels enabling 
subsequent transmigration and on the other one to establish contact and 
synapse formation with APCs [35]. In the latter interaction, LFA-1 initiates 
costimulatory pathways similar to CD28 [31].
Fig. 2: T cell costimulatory molecules. (A) Members of the CD28-B7 family, (B) Costimulatory 
molecules of the TNF receptor family, (C) Members of other pathways. Symbols (+) and (-) 
within the cytoplasmic tails of the receptor molecules depict costimulatory and coinhibitory 
function, respectively. Figure was adapted from Leitner et al. [31].
Tetraspanins are cell surface proteins which contain four characteristic 
membrane-spanning domains [36]. Many tetraspanins are regulated during 
activation of immune cells involving either up- or downregulation. On the 
molecular level some tetraspanins have been shown to interact with integrins, 
the T cell CD4/CD8 coreceptors, but also with members of their own family [36].
In the context of costimulation, the function of tetraspanins has usually been 
studied using antibody-mediated ligation or via loss-of-function studies, even 
though for some family members interaction partners have been found, e.g. 
HCV-E2 interacts with the tetraspanin CD81 [31]. Another tetraspanin which is 
targeted in this study for costimulatory reasons is CD63. A monoclonal antibody 
binding to CD63 was found to act costimulatory if bound to a plate resulting in T 
cell proliferation, cytokine production and induction of anti-apoptotic pathways 
similar to CD28 costimulation [37]. Additionally, it was shown that T cells 
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primarily activated via CD3 and CD63 antibodies respond even more readily to 
restimulation than in the context of a primary CD3/CD28 stimulus thus indicating 
a potent costimulatory role for this tetraspanin [37].
1.7. T cell tolerance
Immunological tolerance is defined as a state of unresponsiveness towards self 
or foreign antigens [38]. While protective immune responses are essential for 
clearance of pathogens immunological tolerance is required towards self
antigens [1, 2]. T cell unresponsiveness towards the latter plays a central role 
for the establishment and maintenance of tolerance. Mechanisms involved are 
clonal deletion via apoptosis, the induction of anergy, active suppression of T 
cell responses and antigen sequestration. T cell tolerance is achieved in central 
and peripheral lymphoid organs, thus being termed central and peripheral 
tolerance, respectively [38, 39].
T cell central tolerance
The establishment of T cell central tolerance is based on the selection of T 
lymphocytes during their development in the thymus [2, 5, 8, 39].
The selection process of thymocytes takes place at the CD4+/CD8+ double-
positive stage after the rearrangement of the TCR. After this step, immature 
cells are destined to undergo apoptosis or “death by neglect” unless they are 
rescued by a weak signal through the TCR by interaction with self-peptide-MHC 
complexes provided by cortical thymic epithelial cells (cTECs) [38,39]. Most of 
the peptides interacted with during positive selection are not unique to the 
epithelial cells, but involve peptides from other tissues of the body. Explanations 
for the necessity for immature cells to weakly react to self antigens involve the 
requirement for self-MHC restriction, i. e. T cells have to be able to recognize 
foreign peptides displayed on self-MHC molecules. Another aspect might be 
that T cells might require low levels to stay alive in the periphery as cells 
transferred into MHC-deficient hosts gradually disappear [38].
During the overall process of positive selection more than 95% of thymocytes 
undergo apoptosis due to the lack of reactivity of their TCR. After positive 
selection the cells enter the single-positive stage. Depending on the reactivity to 
MHC class I or class II either the CD8 or CD4 coreceptors are retained [38,39].
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Furthermore, the expression of chemokines is induced which leads the selected 
thymocytes to the thymic medulla for further maturation [39].
Negative selection is performed towards T cells reacting strongly to self 
antigens which are abundantly expressed in the medulla. However, medullary
thymic epithelial cells (mTECs) seem to express a wider array of self-antigens 
than cTECs [39]. Generally, expression of self-antigens is controlled by the 
transcription factor autoimmune regulator (AIRE) the loss of which was shown 
to result in excessive autoimmunity [40].
Negatively selected T cells undergo apoptosis or clonal deletion. This process 
involves specific dendritic cell subsets which are only found in the medulla [38]. 
It is assumed that DCs acquire self-antigens from mTECs involving 
phagocytosis of dead cells as well as obtaining material from living cells, e.g. 
via exosomes [39].
Apotosis induced upon negative selection also seems to be dependent on 
costimulation or Fas. While moderate self-reactivity seems to require 
costimulation while being independent of Fas, strong TCR avidity for self-
peptides initiates apoptosis in a Fas-dependent form [39].
The thymus is also the induction site for CD4+CD25+FOXP3+ natural T 
regulatory cells. Tregs display moderate to high avidity for self-antigens and are a 
means for non-deletional tolerance induction in the periphery. However, it is 
unclear how Tregs are rescued from apoptosis in order to find a different fate 
[39].
T cell peripheral tolerance
Although most autoreactive T cells are efficiently deleted in the thymus some 
cells which are reactive towards self-antigens escape to the periphery [41]. 
Typically, these cells display relatively weak TCR avidity towards self antigens. 
However, even in the absence of active immunosuppression these cells may 
not necessarily act autoreactive due to the phenomenon of immunological 
ignorance. Naïve T lymphocytes show a restricted circulation pattern involving 
migration from the blood to the lymph nodes which is subsequently re-entered 
via efferent lymphatics [41]. Tissue-specific expression of some antigens limits
the access of naïve T cells to their respective self-antigen, thus avoiding the 
encounter with self-peptide-MHC complexes. Effector-memory T lymphocytes 
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display a more efficient entry into peripheral tissues. However, they only pose a 
serious threat in terms of autoimmunity if TCR re-ligation occurs under 
inflammatory conditions [41].
A major cell type involved in peripheral T cell tolerance mechanisms are 
dendritic cells. While being highly efficient in activating T cells in a mature state, 
immature DCs are poorly immunogenic [42]. 
Dendritic cell populations undergoing migration from peripheral tissues to the 
draining lymph nodes in the steady-state (i.e. in the absence of inflammation) 
were found to act tolerogenic on T cells. Characteristically, these cells display a 
semi-mature phenotype and are capable of inducing either FOXP3+ adaptive T 
regulatory cells (aTregs) or FOXP3
- Tr1 cells which are IL-10 producers [43].
The induction of tolerogenic dendritic cells (tDC) is thought to be influenced by 
factors in their local microenvironment. For example, DCs in the gut are typically 
associated with tolerance induction which is assumed to be dependent on anti-
inflammatory factors like TGF-??? ????????? ?????? ??-10 or thymic stromal 
lymphopoietin (TSLP) [42].
Negative costimulatory or coinhibitory molecules also play a major role in the 
maintenance of T cell tolerance, including CTLA-4 and PD-1. Knockout studies 
in mice indicate an early role for CTLA-4 in control of homeostatic T cell 
proliferation as mice deficient in CTLA-4 die soon after birth. PD-1 deficiency 
requires several months for the onset of autoimmunity which is restricted to 
certain tissues. Although not directly pro-apoptotic, signalling through both 
receptors antagonizes the induction of survival factors which favours activation-
induced cell death [44]. Coinhibitory signals are also associated with the 
induction of T cell anergy [33, 44].
1.8. T cell anergy
T cell anergy is a mechanism of peripheral tolerance induction where T 
lymphocytes are still alive but hyporesponsiveness to antigenic stimulation [45]. 
Basically, two forms of anergy are distinguished; “clonal anergy” and “adaptive 
tolerance” which is also termed “in vivo anergy”. Clonal anergy mainly 
represents a state of growth arrest while the latter state also involves inhibition 
of T cell effector functions [
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Clonal T cell anergy can be induced via a strong TCR signal without 
costimulation or via a weak signal in the presence of costimulation. The state is 
associated with reduced production of IL-2 reflecting the growth arrest but not 
necessarily of other cytokines. Typically, clonal anergy can be reversed by 
addition of exogenous IL-2 [45].
Adaptive tolerance has been described in vivo in the persistence of antigen 
involving rapid T cell expansion followed by a gradual decline of cell numbers. 
Remaining cells are hyporesponsive to restimulation and display a reduction of 
several other cytokines besides IL-2. Upon antigen removal most T cells lose 
their anergy within a week. This is different to clonal anergy where the 
unresponsive state can last for months. However, in most models of in vivo 
anergy IL-2 was not sufficient to reverse the hyporesponsive state [45].
Molecular factors maintaining clonal T cell anergy
Although in principal a growth arrest state, clonal anergy is associated with the 
induction of a distinct transcriptional program involving signalling molecules, 
transcription factors [46] and cell cycle regulators [47]. Additionally, clonal 
anergy might also be maintained via chromatin remodelling [33].
The initial signalling process promoting the induction of anergy is usually 
described as a defect in TCR signalling pathways. While calcium signals 
promoting the nuclear translocation of NFAT are intact, defective activation of 
the Ras/MAPK pathway leads to the diminished activation of AP-1 (Fig. 3). The 
resulting imbalance of signals impairs the transcription of the genes dependent 
on the NFAT-AP1 heterodimer while favouring NFAT-dependent genes which 
include anergy-associated genes [46]. Clonally anergic T cells also display 
impaired activation of NF-?B which is characterized by a lack of I?B degradation 
upon T cell activation [97].
E3 ubiquitin ligases
Many cellular processes are regulated by ubiquitylation, where the small protein 
ubiquitin is linked to lysine residues of target proteins [48]. Depending on the 
type of ubiquitylation different outcomes are achieved including for example 
proteasome-mediated degradation or cellular relocation of a protein. The 
ubiquitylation process is achieved by the action of three enzymes: the ubiquitin-
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activating enzyme E1 binds ubiquitin via a thioester linkage which is then 
transferred to the ubiquitin-conjugating enzyme E2 forming a complex with the 
ubiquitin ligase E3. E3 binds to degradation signal sequences of target proteins 
and aids in the transfer of the polyubiquitin chain to lysines [48].
E3 ubiquitin ligases have been shown to play important roles for the induction 
and maintenance of T cell anergy [46].
Fig. 3: Signalling pathways involved in clonal anergy induction. Defective activation of the 
Ras/MAPK pathway and excessive mobilization of Ca2+ leading to NFAT activation are 
assumed to be the main pathway in the induction of anergy. Fig. was adapted from Zheng et al. 
[46].
The most well-known E3 ubiquitin ligase is Casitas B cell lymphoma b (CBL-b). 
CBL-b has a decisive role in the negative regulation of TCR signals as it targets 
the p85 subunit of phosphoinositide-3-kinase which thus cannot associate with 
the TCR or CD28 [49]. This subsequently leads to the inhibition of NF?B 
activation via PKC? and Akt and prevents cytoskeletal rearrangements via 
Vav1. CBL-b deficiency in mice results in severe autoimmunity [49].
Deletion of the E3 ligase Itch leads to a dermatitis-type inflammation of the skin 
accompanied by constant itching [33]. Itch ubiquitylates the Th2-specific 
transcription factor JunB leading to its degradation. Itch deficiency is associated 
with an increased production of IL-4 and IL-5 as well with elevated IgG1 and IgE 
serum levels [33, 49]. Other targets of Itch within TCR signalling pathways are 
PLC? and ?????which are subsequently degraded within the proteasome [33].
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Gene related to anergy in lymphocytes (GRAIL) is a type I transmembrane 
protein which is localized in endosomes [49]. GRAIL is strongly induced in 
anergized T cells and is sufficient to render T cells anergic in overexpression 
experiments [49]. A putative target of GRAIL is the Rho guanine dissociation 
inhibitor which is stabilized by ubiquitylation and thus inhibits activation of the 
RhoA GTPase, another important factor in TCR signalling. Other likely targets 
are transmembrane proteins such as CD40L and the tetraspanins CD151 and 
CD81 [49]
Transcription factors
The early growth response genes Egr2 and Egr3 are zinc finger transcription 
factors which are highly implicated in the induction of the anergic state [46].
Both Egr genes are strongly transcribed upon TCR stimulation. However, 
costimulation via CD28 significantly reduces the level of Egr mRNA [50]. 
Overexpression of Egr proteins results in decreased synthesis of IL-2 by T cells 
and seems to regulate the transcription of other anergy factors including CBL-b 
and diacylglycerolkinase ?? ????-???? ?????????????? ??????????? ??? ????? ????
shown to confer resistance to anergy induction [46].
Proteins expressed in quiescent cells may also serve the maintenance of 
anergy. DNA binding zinc finger proteins including Ikaros, Blimp-1, p50 
homodimers ??? ????? ???? ???-Smad heterodimers are highly expressed in 
resting cells and mediate the transcriptional repression of the il2 gene via 
recruitment of histone deacetylases (HDAC) [51]. HDAC activity maintains 
histones at the il2 promoter in a hypoactetylated form which is transcriptionally
inactive. Converting the promoter into an active conformation via chromatin 
remodelling is dependent on CD28 costimulation [51].
Diacylglycerol kinases
Diaclglycerol (DAG) is an important activator of the Ras/MAPK and PKC?-
?????????? ????? ??????????? ????????. Diacylglycerol kinases (DGK) mediate 
conversion of DAG into phosphatidic acid thus impairing activation of both
pathways [52]. DGK-?? as well as DGK-?? have been associated with anergy 
induction since deficiency in either gene has been shown to result in resistance 
to anergy induction. Conversely, DGK-?????????????????????????????????????????
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induce anergy in T cells [52]. Although T cells deficient in either DGK are 
hyperresponsive to TCR stimulation autoimmune disease only develops in 
double-knock out mice suggesting a potential redundant function of these 
kinases [52].
Cell cycle-associated factors
Anergy induction seems to be closely linked to cell cycle progression of 
activated T cells. Although costimulation via CD28 during a primary response is 
commonly associated to be sufficient for escaping anergy this only holds true 
for cells undergoing several rounds of cell division while expressing high levels 
of IL-2 and IFN-? [47]. Cells who fail to divide during the primary response do 
not produce IL-2 and are hyporesponsive to secondary stimulation even though 
provided with both, a full signal 1 and signal 2 [47].
Fig. 4: Phases of the cell cycle and their regulation via cyclins, cyclin-dependent kinases 
(CDK) and CDK inhibitors. CDK activity is regulated via expression of associating cyclins at 
different stages of the cell cycle. CDK activity is antagonized via inhibitors of the Cip/Kip and 
Ink4 family. Figure was adapted from Schmetsdorf et al. [53]
In terms of cell cycle progression the transition from G1 into S phase seems to 
be essential for anergy avoidance, as the use of pharmacological inhibitors for 
G1 progression renders T cells anergic even in the presence of full stimulation 
while a block in the S phase fails to do so [47].
On the molecular level cell cycle progression is regulated by the activity of 
cyclin-dependent kinases which are associated with different cyclins depending 
on the phase of the cycle (Fig. 4). While CDK levels remain relatively constant 
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throughout the cell cycle, cyclins display an oscillating expression pattern. 
Additionally, the activity of CDK inhibitors is required for the regulation of 
different cell cycle stages [54].
In order to traverse the G1 phase of the cell cycle activated cells require CDK4 
and CDK6 kinases which are both regulated by D-type cyclin activity as well as 
CDK2 which is dependent on cyclins of the E-type [47]. CDK activity results in 
the hyperphosphorylation of the retinoblastoma protein (Rb) which promotes the 
release and activation of E2F transcription factors ultimately leading to the 
synthesis of S phase proteins [55]. While activation of CDK6 and cyclin D2 is 
unaffected in anergic T cells, cyclin E as well as CDK2 and CDK1 activity 
cannot be induced [47]. Anergic T cell clones do assemble Cyclin D2-CDK4 
holoenzymes. However, there is a lack of kinase activity which is due to the 
association with p27kip1, a CDK inhibitor [55]. p27kip1 presumably plays a dual 
role. While aiding in the cell cycle entry of naïve quiescent T cell by protecting 
D-type cyclin-CDK4/6 complexes from degradation via ink4 CDK inhibitors in 
the first cell division, it acts as negative regulator by additionally inhibiting
CDK1/2 activity in ensuing cell divisions [47]. Loss of p27kip1 was shown to 
uncouple T cell activation from the need of costimulation as silencing of the il2
locus does not occur [47]. However, its role as an essential anergy factor has 
been challenged by models where anergy could be induced despite lack of 
p27kip1expression [56, 57].
1.9. T cell quiescence
The term quiescence corresponds to the G0 phase of the cell cycle, a state 
where cells display markedly reduced size, metabolism, protein synthesis and 
transcriptional activity [58, 59]. Unlike anergy quiescence is characterized by 
responsiveness to activation as well as resistance to apoptosis. Quiescence is 
governed by a distinct transcriptional program by factors which are actively 
suppressed upon activation and cell cycle entry [58, 59].
A classical factor in T cell quiescence is Krüppel-like factor 2 (KLF2) or lung 
KLF (LKLF) the latter name being derived from its high expression levels in lung 
tissue [60]. KLF2 is a zinc finger transcription factor which is profoundly 
expressed in naïve T cells and resting memory cells. Activation mediates rapid 
downregulation of KLF2 [58].
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KLF2 deficiency in mice leads to pronounced defects in T cell development 
resulting in dramatically reduced T cell numbers. Remaining T cells bear 
activation markers leading to spontaneous proliferation and subsequent Fas-
dependent apoptosis [58]. Consistent with this is the observation that KLF2 
overexpression is sufficient to induce growth arrest accompanied by a decrease 
in size and metabolic activity and transferrin receptor expression in the T cell 
leukaemia line Jurkat. Further studies identified the proto-oncogene Myc as a 
target of KLF2 which is negatively regulated upon overexpression of the latter
[58]. Putative targets of c-Myc involve p27kip1, complexes of CDK4/CDK6 with 
cyclin D1 as well as the phosphatase cdc25. The latter dephosphorylates CDK2 
at inhibitory sites [59].
Other factors involved in T cell quiescence involve Tob, a member of the anti-
proliferative (APRO) family and forkhead box O (FOXO) family members [58, 
59] and Schlafen 2 (slfn2) [66].
1.10. The Schlafen gene family
The Schlafen gene family was first identified in the mouse as a family of growth 
regulatory genes which are preferentially expressed in lymphoid tissues and 
whose members were found to be differentially regulated during thymocyte 
development [61]. Already in the initial study a link between Schlafen genes and 
growth control was established since Slfn1 was reported to induce a cell cycle 
arrest in fibroblasts before the transition from G1 to S phase [61]. The 
mechanism of growth arrest seems to occur via suppression of cyclin D1 
expression [62]. However, the in vitro growth inhibitory action of Slfn1 as well as 
of Slfn2 was not always confirmed by others [63]. Schlafen genes have also 
been shown to be regulated during T cell activation [61, 64, 65]. A role for 
Schlafen family members in immune cell quiescence was suggested by a study 
characterizing a mutation in Slfn2 which lead to lineage-specific defects in 
monocytes and T cells. The latter were found to reside in a semi-activated state
and cells of both lineages rapidly died in response to activation signals 
suggesting a loss of cellular quiescence [66]. Schlafen-like proteins have also 
been identified in orthopoxviruses implicating importance for viral immune 
evasion [67].
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All proteins of the Schlafen family share a common core reagion which harbours 
a divergent AAA (ATPases associated with various cellular activities) domain 
(Fig. 5A) functioning as an ATP-binding site and a conserved domain signature 
(COG2865) which is found in transcriptional regulators and helicases [65-67].
The AAA motif is a highly conserved domain found in eukaryotes as well as in 
prokaryotes. Although AAA proteins are very homologous within this domain 
other sequences show little conservation. The diverse cellular functions exerted 
include, for example, fusion of membranes during vesicular transport, protein 
quality control as well as functions as microtubule-associated motor proteins 
[101]. The ATPase domain common to this class of proteins is assumed to 
provide energy through ATP hydrolysis enabling remodelling of substrates. 
Additionally, ATP-binding might aid in the formation and stabilization of ring-
shaped hexamers which is a typical feature of AAA proteins [101]. SLFN family 
members are divided into three subgroups based on their length and domain 
composition. Members of subgroup III within the SLFN family share motifs 
within their C-terminal domain homologous to superfamily I RNA/DNA helicases 
[65].
Little is known about the function of the six human Schlafen family members. A 
study investigating the expression of SLFN genes in primary human 
melanocytes and malignant melanoma cell lines showed basal expression of 
human SLFNs in both cell types [68]. All SLFN genes were found to be 
inducible in primary human melanocytes upon treatment with IFN-????????????
only SLFN5 was consistently suppressed in all melanoma cell lines observed 
and was the only IFN-?-inducible SLFN gene in these cells. Knock-down of 
SLFN5 resulted in increased anchorage-independent growth and invasion of 
malignant melanoma cells [68].
Growth inhibitory function or implication in T cell quiescence has not been 
shown for human SLFNs so far. Although having no direct orthologue in the 
mouse SLFN12 seems to be the most similar of human SLFN genes to the 
novel T cell quiescence factor Slfn2 [66]. According to its domain structure 
SLFN12 can be classified as a member of SLFN subgroup II (Fig 5B). 
Expression data for this factor is limited. Similar to other SLFN genes, SLFN12 
was shown to be upregulated in primary human melanocytes upon IFN-??
treatment and seems to be suppressed in some melanoma cell lines [68]. 
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Another study showed upregulation of SLFN12 during the LPS stimulation of 
human monocyte-derived macrophages [70]. To date, expression of SLFN12 
has not been characterized in T cells or other lymphocytes.
A
B
Subgroup Murine Slfns Human SLFNs
I slfn1, slfn2
II slfn3, slfn4, slfn14 SLFN12, SLFN12L, SLFN14
III slfn5, slfn 8, slfn9, slfn10 SLFN5, SLFN11, SLFN13
Fig. 5: Domain structure of SLFN proteins and division into subgroups. (A) Scheme of 
domain structures of SLFN family members. (B) Subgroups of human and murine SLFN family 
members. Based on Bustos et al. [67] and on search results in NCBI conserved domain search 
[69].
1.11. CD45 as a regulator of TCR signalling
The common leukocyte antigen CD45 is the prototypic receptor-like protein 
tyrosine phosphatase (PTP) and has been shown to be essential in the 
regulation of signal transduction pathways in immune cells [71]. CD45 is 
abundantly expressed on all nucleated hematopoietic cells and their precursors 
and displays type I transmembrane topology [72]. While the cytoplasmic part of 
CD45 appears to be highly conserved across mammalia, its extracellular 
domain reveals little sequence homology. Alternative splicing of the extracellular 
domain gives rise to various isoforms the expression of which is dependent on 
cell type, developmental stage and activation state [71] The extracellular 
domain shows three conserved regions involving carbohydrate linkage sites 
followed by a region rich in cysteine residues and three fibronectin type III 
domains [73].
Subgroup
I
II
III
RNA/DNA helicase domainAAA_4 domain
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The cytoplasmic tail of CD45 consists of two tyrosine phosphatase homology
domains, designated D1 and D2. Only D1 has enzymatic activity, while D2 
might serve as a stabilizer of D1 [71]. 
CD45 seems to regulate signal transduction of the T cell receptor in a positive 
as well as in a negative fashion. Its main substrates are Src family protein 
tyrosine kinases (SFKs) like Lck or Fyn [71].
SFKs contain two sites of tyrosine phosphorylation for the regulation of kinase 
activity. While the inhibitory site is near the C-terminus, an activating site is 
located within the kinase domain [74]. However, despite hyperphosphorylation 
of the negative regulatory tyrosine residue in cell lines and thymocytes deficient 
in CD45, average SFK activity was found to be increased [71]. This observation 
implies that the activating residue also serves as a substrate for CD45 and is 
further supported by the abnormal adherence of CD45-deficient macrophages 
and T cells which is dependent on integrin receptor signalling regulated via 
SFKs [71]. 
The function of the extracellular domain of CD45 lies in the regulation of
phosphatase activity via differential dimerization of isoforms [71]. Dimerization 
seems to be regulated via sialylation and O-glycosylation of the alternatively 
spliced exons. As a result, the smallest isoform RO which is the least modified
homodimerizes more readily than larger isoforms, resulting in decreased TCR 
signalling [75].
1.12. The soluble cytoplasmic tail of CD45 and its action on human T 
cells
Recently, an alternative function for CD45 has been discovered showing that 
CD45 is proteolytically cleaved in activated human monocytes and granulocytes 
upon stimulation with the fungal cell wall component zymosan or phorbol 12-
myristate 13-acetate (PMA) but not by any other microbial stimulus [76]. Both 
stimuli are potent inducers of the respiratory burst in phagocytes, which was 
found necessary for CD45 cleavage. A critical step involved in burst formation 
via zymosan might be the ligation of Dectin-1 [76]. Following activation and 
recruitment of the NADPH oxidase CD45 is sequentially cleaved by
??????? ???????????????? ???? ?-secretase leading to the shedding of the 
ectodomain and the generation a 95 kDa fragment of the cytoplasmic tail of 
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CD45 (ct-CD45). This fragment was found to be released upon activation-
induced cell death [76]. 
Fig. 6: ct-CD45 generation upon activation of human granulocytes and monocytes. Upon 
activation-induced cell death ct-CD45 is released and binds to human T cells via the putative 
receptor PRAT4A.
Binding studies determined that ct-CD45 acts as a cytokine-like factor on 
human T cells and was shown to inhibit the proliferation of these cells upon in 
vitro upon stimulation with CD3 and CD3/CD63 antibodies as well as in 
allogeneic mixed leukocyte reactions [76, 77]. Inhibition of T cell proliferation 
was shown to be independent of phosphatase activity as fusion proteins 
consisting of D2 or a phosphatase-dead D1 showed inhibitory action. The 
reduced proliferation of these cells is not due to cell death [76]. Furthermore it 
was shown that even T cells activated via CD3/CD28 antibodies do not show 
impaired proliferation upon ct-CD45 challenge. However, most strikingly, it was 
demonstrated that even these cells display reduced production of all cytokines 
tested as well as an impairment in the induction of T cell activation markers [77].
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Further experiments showed that ct-CD45-treated T cells are hyporesponsive to 
restimulation which could be partly reversed by exogenous IL-2 [77]. A potential 
receptor candidate for ct-CD45 was identified by a cDNA library screen showing 
binding of ct-CD45 to a protein associated with TLR4 (PRAT4A) on the cell 
surface [77]. PRAT4A was originally described as an endoplasmic reticulum 
resident protein involved in the regulation of TLR4 surface expression [78].
Following studies found that PRAT4A is important for immune responses via 
several TLRs by regulating maturation of TLRs within the ER including TLR1 
and TLR4 as well as the subcellular distribution of TLR7 and TLR9 [98]. Since 
prior reports suggest a role for PRAT4A as an ER chaperone surface 
expression of this molecule including a receptor function for ct-CD45 appeared 
to be quite surprising. Nevertheless, evidence for this was provided by showing 
cells surface expression of PRAT4A on a Bw 5417 clone overexpressing human 
PRAT4A as well as on human T cells following activation [77]. A siRNA-
mediated knock-down of PRAT4A in the Bw clone showed reduced binding of 
ct-CD45 to the cells which also supported its receptor function as obtained by 
the screen [77]. However, a physical blockade of ct-CD45 binding via PRAT4A 
antibodies could not be achieved so far. Besides, the question regarding 
molecular factors regulating this anergic state of human T cells still remained.
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2. Aim
The pronounced inhibition of T cell proliferation by ct-CD45 accompanied by 
hyporesponsiveness to restimulation suggested an anergy-like state bearing 
similarities as well as differences to classical anergy. Since this anergy-like 
state is regulated by biochemical events the major aim of this study was to 
elucidate the molecular mechanisms involved in its maintenance. T cell anergy 
is based on a distinct transcriptional program [56-57] involving actively 
regulated factors such as signalling molecules, transcription factors and cell 
cycle regulators. Therefore, the specific aims of the study were:
1. To broadly identify responsible factors for this anergy-like state via the 
microarray technology.
2. Then to confirm and further analyze differentially expressed factors by 
quantitative real-time PCR. 
Fig. 7: Experimental procedure for the identification of molecular factors induced by ct-
CD45 in human T cells creating an anergy-like state.
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3. Materials and Methods
3.1. Antibodies, fusion proteins and oligonucleotides
Antibodies
species specificity clone isotype source
mouse hu CD3 OKT3 IgG2a Jansen-Cilag, Vienna, AT
mouse hu CD28 15E8 IgG1
Caltag Laboratories, 
Burlingame, CA
mouse hu CD63
CD63 -
11C9
IgG3
Otto Majdic, Institute of 
Immunology
rabbit SLFN12 (N-term.) polyclonal IgG Abcam, Cambridge, UK
rabbit SLFN12 (C-term.) polyclonal IgG Abcam, Cambridge, UK
rabbit hu KLF2 polyclonal IgG Sigma-Aldrich, St. Louis, MO
rabbit mu+hu PRAT4A polyclonal - Kensuke Miyake, Tokyo, JP
goat human IgG polyclonal IgG
Jackson Immunoresearch Lab., 
West Grove, PA
goat murine IgG polyclonal IgG
Jackson Immunoresearch Lab., 
West Grove, PA
goat human IgG-PE polyclonal IgG
Jackson Immunoresearch Lab., 
West Grove, PA
goat rabbit IgG-HRP polyclonal IgG
Dako Diagnostics AG, Glostrup, 
DK
Abbreviations: hu……human
   mu…. murine
   term…terminus
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Fusion proteins
fusion protein source
ct-CD45-Fc Stefan Hopf and Alexander Puck, Institute of Immunology, Vienna
CTLA-4-Fc Bristol-Meyers Squibb, NY
Primers used for qPCR
primer sequence 5'->3'
ACTB_F AGAGCTACGAGCTGCCTGAC
ACTB_R AGCACTGTGTTGGCGTACAG
??-m_F GATGAGTATGCCTGCCGTGTG
??-m_R CAATCCAAATGCGGCATCT
CBL-b_F ATGCTGAATGGAACACATGG
CBL-b_R ACTATGCCTTGCAGGAGGTG
CD3E_F TGAGGGCAAGAGTGTGTGAG
CD3E_R TCCTTGTTTTGTCCCCTTTG
CDK1_F GGTCAAGTGGTAGCCATGAAA
CDK1_R TCCTGCATAAGCACATCCTG
CDK2_F TTGTCAAGCTGCTGGATGTC
CDK2_R TTTAAGGTCTCGGTGGAGGA
CDK4_F TTCTGGTGACAAGTGGTGGA
CDK4_R CTGGTCGGCTTCAGAGTTTC
CDK6_F TGTTTCAGCTTCTCCGAGGT
CDK6_R CGTGACGACCACTGAGGTTA
cyclin D1_F CAAATGTGTGCAGAAGGAGGT
cyclin D1_R AGGAAGCGGTCCAGGTAGTT
cyclin D2_F CTGGGGAAGTTGAAGTGGAA
cyclin D2_R ATCATCGACGGTGGGTACAT
cyclin E1_F AATGCGAGCAATTCTTCTGG
cyclin E1_R CTGGTGCAACTTTGGAGGAT
Materials and Methods
45
primer sequence 5'->3'
EGR3_F CAACTGCCTGACAATCTGTACC
EGR3_R AGTAGGTCACGGTCTTGTTGC
GAPDH_F CGACCACTTTGTCAAGCTCA
GAPDH_R AGGGGAGATTCAGTGTGGTG
IFNg_F TTCAGCTCTGCATCGTTTTG
IFNg_R TCTTTTGGATGCTCTGGTCA
KLF2_F CTACACCAAGAGTTCGCATCTG
KLF2_R AGTTGCAGTGGTAGGGCTTC
p27kip_F CCGGCTAACTCTGAGGACAC
p27kip_R AGAAGAATCGTCGGTTGCAG
SLFN11_F CCTCCCCTTAGCAGACCAGT
SLFN11_R TTCCCCGAAAGAAAGGTTG
SLFN12_F CAAGCCAACCAGGAGAAAAG
SLFN12_R AACCAACTCGGCATAATTCG
SLFN12_“B“_F AACCGTGTGATGCAGTTGAC
SLFN12_“B“_R TTCTGCAAAGGTTTTCTGGAG
SLFN12L_F TTGACCGAGAAGGAATGGAT
SLFN12L_R GCAGAAGGTTTTTGGAGCAC
SLFN13_F GACGCAGATCCAGAGTTTCC
SLFN13_R AAATGTCCTGGTGGAACTGG
SLFN14_F TCAGTCAGCTCCTCCCAGTT
SLFN14_R CAAGGATGTATCAGGGTCTTCA
SLFN5_F AATTGCCCACAAGAGAATGG
SLFN5_R AGCGTTTCTGCTGCTCTTTC
All primers were synthesized by Sigma-Aldrich (Steinheim, DE). Primer 
sequences for CD3E [94], CBL-??? ????? ????? ???? ??-microglobulin [96] have 
been described previously. Sequences for the IFN-?? ??? ???? ????? ?????????
from Dr. Peter Steinberger (Institute of Immunology). Another SLFN12 primer 
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used in some experiments was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).
siRNA
target sense strand of duplex
SLFN12 GCAAUUCUGGUCUUAAAUACAAUCUCC
SLFN12 CAUCACACGGUUAUCUUUCACAUGCCA
SLFN12 GUGAGCCUUCGACAAGAUUUAAACAUC
The SLFN12 Trilencer-27 siRNA and a Trilencer-27 Universal Scrambled 
Negative Control siRNA Duplex were purchased from Origene Technologies 
(Rockville, MD).
Buffers and media
LB medium: 25 mg Luria Broth Base per litre of distilled water; boil to dissolve 
and autoclave before use.
Heparin medium: 500 ml RPMI 1640 medium + FCS. Add 100 U/ml penicillin + 
100 ?g/ml streptamycin and 2mM L-glutamine (stored at –20°C, Sigma-
Aldrich)). Add 10 U/ml Heparin (stock: 5000 U/ml, Baxter, Vienna).
Freezing medium: RPMI 1640 supplemented with 25% FCS and 10% DMSO
MACS-buffer (stored at 0°C): 1000 ml 1x PBS def. + 25 ml Human Serum 
Albumin (stock: 20%, Centeon, Vienna) + 10 ml EDTA (stock: 0,5 M); sterile 
filtration.
10x PBS stock solution: 
5.8 g KH2PO4
16.6 g Na2HPO4 2H2O 
72 g NaCl 
Dissolve in aquabidest (=ddH2O), fill up to 10 litres and adjust to pH 7.2
PBS/BSA stock solution (20%):
100 g BSA 
10 g NaN3
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Dissolve in 500 ml PBS buffer. For the PBS/BSA wash buffer, prepare a 1:20 
dilution with PBS buffer.
Solutions for western blot:
Running buffer (4x):
Tris 12 g
SDS 4 g
Glycin 57,6 g
Fill up to 1000 ml with ddH2O
Blotting Buffer:
250ml of 4x running buffer
200 ml methanol
ad ddH2O to 1000 ml. Degas before use.
PBST (PBST 0.5%):
PBS with 0.5 % Tween 20
Dry milk solution
5% dry milk powder dissolved in PBST buffer.
List of reagents and chemicals
Reagent final conc. source
Beriglobin 20 mg/ml (in PBS/BSA)
Aventis Behring, Vienna, 
Austria
Glycogen 130 µg/ml
Fermentas, Burlington, 
Canada
GM-CSF 50 ng/ml
Novartis Research Institute,
Vienna
IL-4 100U/ml
Novartis Research Institute,
Vienna
LipofectamineTM 2000 1:150
Life technologies, Carlsbad, 
CA
methyl-3H-thymidine 1mCi/ml Perkin Elmer, Waltham, MA
pegGOLD TriFastTM undiluted PeqLab, Erlangen, DE
OPTI-MEM® undiluted
Life technologies, Carlsbad, 
CA
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Cell lines
The following cell lines were used in this study: The Jurkat cell line was 
obtained from American Type Culture Collection (ATCC, Manassas, VA). The 
SK-N-SH cell line was a gift from St. Anna Children’s Cancer Research 
Institute, Vienna. Murine Bw 5417 cells were kindly provided by Dr. Peter 
Steinberger (Institute of Immunology, Medical University of Vienna). Phoenix-E 
cells were a gift from G. P. Nolan (Stanford University, Stanford, CA).
3.2. Cell isolation
Cell preparation
Peripheral blood mononuclear cells were separated from whole blood of healthy
donors by density gradient centrifugation using Ficoll-Paque (Amersham, Little 
Chalfont, UK). Blood was diluted 1:2 to 1:3 with heparin-medium. For density
gradient centrifugation 15 ml of Ficoll-Paque were prepared in 50 ml tubes and
a layer of heparinized blood was carefully pipetted onto. The cells were spun 30
minutes at 900g without brake. After centrifugation granulocytes and
erythrocytes gathered at the bottom of the tube, mononuclear cells in the
interphase.
Magnetic activated cell sorting (MACS)
Magnetic activated cell sorting (MACS) is a method for the selective enrichment 
or depletion of cells which express a surface protein distinct for their cell type.
Therefore cells can be labelled with antibodies directed against the specific
molecule which have been coupled to biotin. These labelled cells can be
targeted with magnetic beads that contain a secondary antibody targeted
against the biotin residues on the primary antibody. Therefore, specific cells in a
mixture can be selectively retained in a magnetic column. The mAbs we used 
were labelled with biotin. These biotinylated antibodies recognizing cell-type 
specific surface molecules were mixed with the cells to be separated. Then the 
cells were washed twice with MACS-buffer. In a second incubation step 
paramagnetic beads (50 nm in diameter) were coupled to the cells. The cells 
were applied onto a separation column placed in a strong permanent magnet. In 
this strong magnetic field the cells labelled with paramagnetic beads stack to 
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the iron mesh and were retained while non-labelled cells passed through. 
Retained cells were eluted by removing the column from the magnetic field.
Purification of T cells and monocytes
For the isolation of monocytes up to 1 x 109 PBMCs were incubated with 250?l 
of biotinylated CD14 (VIM13) and positively enriched (positive selection),
whereas T cells were isolated by collecting the flowthrough of PBMCs depleted 
(negative selection) by using an antibody cocktail containing anti-CD14 
(monocytes), anti-CD16 (monocytes, NK–cells), anti-CD19 (B cells), anti-CD36 
(monocytes, thrombocytes), anti-CD56 (NK-cells) and anti-CD123 (progenitor 
cells, megakaryocytes, granulocytes). Freshly isolated PBMCs were 
resuspended in 750 ?l MACS buffer and incubated with 250 ?l of biotinylated 
antibodies for 15 minutes at 4 °C. To remove unbound antibodies the cells were 
washed with MACS buffer and again resuspended in 750 ?l buffer. Then 250 ?l 
of anti-Streptavidin MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
were added to the suspension and incubated for 15 minutes at 4°C. In the 
meantime a CS column (Miltenyi biotec) was placed onto a VarioMACS 
apparatus and equilibrated with 40 ml MACS buffer. Afterwards the labelled 
PBMCs were loaded onto the column and washed with 40 ml MACS buffer. The 
flow through was collected as the monocyte-negative fraction. The column was 
further washed 4 times with 10 ml MACS buffer and monocytes were collected 
by removal of the column from the magnet and aspiration of the retained cells 
from the side valve using a syringe. For T cells the flow-through was collected, 
washed with MACS buffer and counted. 20 ?l of this solution were taken for cell 
counting with a Coulter Counter (Beckman Coulter, Miami, FL). Before 
measuring the cell number two drops of Zap-Oglobin® (Beckman Coulter) are 
added to the counting beaker to remove residual erythrocytes.
Freezing and thawing of cells
Mammalian cells can be stored in liquid nitrogen for prolonged periods of time
with minimal loss of viability. For that purpose, cells were spun down, counted
and resuspended in freezing medium to a concentration between 107 – 5 x 
107cells/ml. 1 ml aliquots were filled into cryotubes (Nalgene Nunc International,
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Roskilde, Denmark) and kept overnight at - 80°C in a freezing box filled with
isopropanol before being transferred to liquid nitrogen.
Isolation of naïve T cells from human cord blood
Naive T cells were isolated from cord blood as described above. Cord blood 
samples from healthy donors were collected during healthy full-term deliveries. 
Approval was obtained from the Medical University of Vienna institutional review 
board for these studies.
3.3. Cell culture
Cell Culture conditions
For general cell culture RPMI 1640 (NBK, Novartis Research Institute, Vienna) 
supplemented with 10% FCS (HyClone, Logan, UT), 2 mM L-glutamine (NBK, 
Novartis Research Institute, Vienna), 100 U/ml penicillin and 100 ?g/ml 
streptomycin (NBK, Novartis Research Institute, Vienna) was used. Phoenix-E 
cells were cultivated in IMDM medium supplemented with FCS, L-glutamine,
penicillin, streptomycin and amphotericin. Cells were cultured at 37°C with 5% 
CO2.
T cell activation/inhibition
For T cell activation/inhibition assays antibodies and Ig-fusion proteins were 
used. 96-well non-tissue culture plates (Nunc-immuno plate maxisorp, #439454, 
Nunc, Denmark) were coated with 3 µg/ml of Fc-specific goat anti-mouse IgG 
and goat anti-human IgG (Jackson Immunoresearch laboratories), overnight at 
4°C, washed twice, and then incubated with 2 µg/ml of the respective fusion 
protein (ct-CD45-Fc and CTLA4-Fc) plus anti-CD3 (4 µg/ml) or the combination 
of anti CD3/CD28 or anti CD3/CD63 mAb (2 µg/ml of each antibody). After 
another washing step, T-cells (1-1.5x105 cells/well) were added to the wells.
T cell restimulation 
For restimulation T cells were activated in the presence of fusion proteins as 
indicated above and cultured for 4 days. Cells were then harvested, washed 
twice and rested in 24 well plates for 3 days. 96-well plates were pre-coated 
overnight at 4°C with 3 µg/ml of Fc-specific goat anti-mouse IgG, washed and 
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incubated with CD3/CD63 or CD3/CD28 (2 µg/ml for each antibody). Following 
washing, T-cells (1x105 cells/well) were added to the wells and cultured for 4 
days. Proliferation was assessed as described below.
Cell proliferation assays 
T cell proliferation was monitored in 96-well plates by activating 100.000 
cells/well for 3 days as indicated above. 
On day 3, 1.25 µCi of methyl-3H-thymidine (Perkin Elmer, Waltham, MA) were 
added to each well followed by culturing for another 18 hours. Cells were then 
lysed by distilled water and harvested onto filter plates (Milipore Corp., Bedford, 
MA). Plates were dried for 1 hour at 37°C before addition of 25 µl/well of 
Microscint scintillation mix (Packard, Meriden, Connecticut). Incorporated 
radioactivity was determined using a microplate scintillation counter (Packard). 
All assays were performed in triplicate.
Generation of monocyte-derived DC
Monocyte-derived immature dendritic cells were generated by culturing 
peripheral blood CD14+ monocytes for 7 days in the presence of 50 ng/ml GM-
CSF (Novartis Research Institute, Vienna) and 100 U/ml IL-4 (Novartis 
Research Institute, Vienna).
LPS-challenge of monocyte-derived dendritic cells
1x106 cells in a 24-well plate were treated with 1 µg/ml lipopolysaccharide for up 
to 24 hours. Cells were then harvested and lysed for RNA isolation.
3.4. Generation of fusion proteins
Preparation of fusion protein-encoding plasmid vectors
Plasmids were prepared from glycerol stocks of E. coli cells transformed with a 
pEAK12 vector (Edge BioSystems, Gaithersburg, MD) encoding ct-CD45-Fc 
fusion proteins consisting either of D1, D2 or full length Fc fusion constructs. 
For large scale preparation of plasmids, bacteria were inoculated in up to 500 
ml of LB medium supplemented with ampicillin (70 µg/ml) to grow under shaking 
over night at 37°C. Plasmid maxipreparation was performed with the Qiagen 
Plasmid Maxi Kit, according to the manufacturer’s protocol. Bacterial cells were 
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harvested by centrifugation at 5000 g (4000 rpm) for 15 minutes at 4°C. The 
pellet was resuspendend in 10 ml buffer P1 (Qiagen) before 10 ml of alkaline 
cell lysis buffer P2 (Qiagen) were added, the solution was gently mixed and 
incubated at room temperature for 5 minutes. In the next step 10ml of 
neutralization buffer P3 (Qiagen) were added to stop cell lysis. 
Lysates were incubated on ice for 15 minutes followed by centrifugation at 5000 
g (4000 rpm) for 30 minutes at 4°C to remove cell debris. The supernatant was 
filtered and transferred to a Qiagen tip 500 column, which had been equilibrated 
with 10 ml buffer QBT (Qiagen). After washing the column twice with 30 ml of 
buffer QC (Qiagen), DNA was eluted with 15 ml buffer QF (Qiagen) and 
precipitated by adding 10,5 ml isopropanol. The precipitated DNA was collected 
by centrifugation for 30 minutes at 4°C at 5000 g (4000 rpm). The DNA pellet 
was washed once with 70 % ethanol, dried and resuspendend in nuclease free 
water according to the pellet size. The DNA content was determined by 
measuring the OD at 260nm using a NanoDrop 2000 spectrophotometer 
(PeqLab, Erlangen, DE). Plasmid DNA was diluted to a final concentration of 1 
µg/µl and stored at -20°C until use.
CaCl2 Transfection of Phoenix cells
HBS-Buffer (pH 7,05): 
140 mM NaCl
1,5 mM Na2HPO4
50 mM HEPES
2,5 M CaCl2
24 h before transfection cells were harvested by trypsination and seeded in a 
concentration as indicated below. One hour before transfection fresh medium 
was applied. Plasmid DNA was diluted with sterile ddH2O and CaCl2 (see table 
below). The transfection mix was sterile filtered using a 0,22 µm filter and the 
required amount of 2 x HBS was added while vortexing on low level. Formation 
of DNA-calcium phosphate precipitates was allowed by incubation for exactly 1 
minute at room temperature, before applying the mix drop wisely to the cells. 
After 16 - 24 h the medium was replaced. The supernatants were harvested 3 
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and 6 days after transfection. For generation of immunoglobulin fusion proteins 
6 to 10 ∅10 cm dishes were transfected with the respective plasmid construct. 
Cell number/ml DNA ddH2O CaCl2 2,5 M *) 2 x HBS-
Buffer
10cm plate 6 x 106 30 µg ad 900 µl 100 µl 1000 µl
6-well 1 x 106 6 µg ad 90 µl 10 µl 100 µl
24-well 0,3 x 106 3 µg ad 45 µl 5 µl 50 µl
48-well 2 x 105 1 µg ad 25 µl 2,5 µl 25 µl
optional: use 5 µg of a GFP-Plasmid to monitor transfection 
efficiency
*) add shortly before transfection 
Purification of immunoglobulin fusionproteins
Buffers & solutions
All buffers were sterile filtered (0,22 µm filter) before use:
binding buffer (wash buffer): 20 mM sodium phosphat, pH7
elution buffer: 0,1 M sodium citrat, pH 3
Tris-HCl pH 9 
PBS + 20 % EtOH
dialysis buffer : 150 mM NaCl, 50 mM HEPES, 4 mM DTT, 0,0035% Tween-20, 
pH 7.0
For protein purification of fusionprotein from cell-culture supernatants the 
HiTrap Protein A HP column (GE healthcare, UK) was used. The specifity of 
protein A is primarily for the Fc region of IgG.
The cell culture supernatants of Phoenix cells transfected with a vector 
encoding various ct-CD45-Fc fusion proteins were centrifuged at 2 200 rpm for 
5 min to remove cell debris. Before applying to the column the sample was 
filtered using a 0,22 µm filter.
Using a constant flow rate of 1 ml/min the column was equilibrated with 5-10 ml 
binding buffer, 5-10 ml elution buffer and 5-10 ml binding buffer again. Then the 
sample was loaded to the column. Before elution the column was washed with 
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5-10 ml binding buffer and then 8 x 1 ml fractions were collected. 120 µl of Tris-
HCl pH 9 were added so that the final pH of the sample would be neutral, to 
provide proper folding of the protein. The column was regenerated by washing 
with 5-10 ml binding buffer. For further use and storage (4°C) the column was 
washed with 20 % ethanol in PBS.
After purification the protein concentration of the eluted fractions was measured 
at OD280 (OD1 is equal to 0,7 µg/µl). Then all fractions which contained protein 
were pooled and dialysed o/n at 4°C against dialysis buffer under stirring. At the 
next day the protein concentration of the dialysed fractions was measured 
again. The Fc fusionproteins were aliquoted and stored at –80°C.
3.5. Flow cytometry
Principles
Flow cytometry can be used to examine diverse properties of cells including the 
relative size, relative granularity and relative fluorescence intensity. Cells are 
transported in a fluid stream to a laser beam. To accomplish that single cells are
passing through the beam, a principle related to laminar flow is applied. The
sample is injected into a stream of sheath fluid. Cells within this stream are
accelerated and are focused to the center, a process called hydrodynamic
focussing. The incident laser light is scattered by the cells and detected in 
different angles. Forward scatter light (FSC) is measured just of the axis of the 
incident beam by a photo diode and gives information about the size of a 
particle. Side scatter light (SSC) is collected by a photo-multiplier at 
approximately 90° of the laser beam axis and is proportional to the granularity.
The argon ion laser used emits light at 488 nm, a wavelength matching with the
absorption spectrum of a range of fluorescent dyes. These fluorochromes can
be excited by the laser, which means that an electron is raised to a higher state
of energy. After returning to ground state a photon is emitted and fluorescence
can be detected after passing a system of lenses and filters. The intensities of 
different fluorochromes can be analysed at once, provided that their absorption
maximae are not to close to each other.
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Membrane staining with unconjugated mAb
Unspecific binding of mAbs to Fc?-receptors was blocked by incubation of cells 
with human immunoglobin Beriglobin (Aventis Behring GmbH, Vienna). As an 
isotype-matched control a polyclonal rabbit anti-human KLF2 antibody was 
applied. A phycoerythrin (PE)-conjugated goat anti-rabbit IgG was used for 
secondary labelling.
Firstly, the cell suspension (2-5x105 /assay) was centrifuged for 5 minutes at 
300g and the pellet was resuspended with 50 ?l Beriglobin/assay (20 mg/ml in 
PBS/BSA 1%) and kept 10 minutes on ice. Then 20 ?l of the antibody (20 µg/ml 
in PBS/BSA 1%) were prepared in Micronic tubes and 50 ?l of the cell 
suspension was added, mixed and incubated 30 minutes at 4°C. Each assay 
was washed twice with PBS/BSA 1% followed each time by centrifugation at 
300g, at 4°C. 20 ?l of PE-conjugated antibody (20 µg/ml) were added to the 
cells and again incubated for 30 minutes at 4°C. Each assay was washed twice 
with PBS/BSA 1% resuspending the cells in 50 ?l FACS fluid (Becton 
Dickinson, Franklin Lakes, NJ). The tubes were kept on ice until they were 
analyzed by flow cytometry using a FACScalibur Flow Cytometer (Becton 
Dickinson, Palo Alto, CA)
Binding studies with fusion proteins
Binding studies with fusion proteins were performed analogous to staining with 
unconjugated antibodies. As described above, unspecific binding of fusion 
proteins or antibodies to Fc?-receptors was blocked via human Beriglobin 
(Aventis Behring GmbH, Vienna). CTLA-4 Fc was used as a non-binding control 
fusion protein. A phycoerythrin (PE)-conjugated goat anti-?????? ???? ????-
specific) antibody was used for secondary labelling. For blocking of ct-CD45 
binding to PRAT4A a polyclonal PRAT4A antiserum (kindly provided by Dr. 
Kensuke Miyake, University of Tokyo) at a 1:100 dilution in PBS/BSA 1% was 
incubated for 20 minutes before addition of fusion protein. Fusion proteins and 
secondary antibodies were used at a concentration of ~20 µg/ml.
Binding was analyzed by flow cytometry using a FACScalibur Flow Cytometer 
(Becton Dickinson).
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3.6. mRNA quantitation
RNA-Isolation and cDNA preparation
Total RNA was isolated using peqGOLD TriFastTM reagent (peqLab, Erlangen, 
DE) For isolation 1-2x106 cells/ml were resuspended in 500 µl of TriFastTM
reagent and incubated for 5 minutes (optional: -20°C until need) at room 
temperature. To separate RNA from cellular protein and DNA 100 ?l of 
chloroform were added, mixed by vortexing and incubated again for 5 minutes 
at room temperature. After centrifugation for 15 minutes at 13 000 rpm at 4°C 
the aqueous phase was transferred into a fresh tube and 300 ?l of isopropanol 
as well as 4 ?l of a 20 mg/ml solution of glycogen serving as an inert co-
precipitant were added. The contents were mixed by inversion, incubated for 5 
minutes at RT and centrifuged again at 13 000 rpm at 4°C for 10 minutes. The 
pellet was washed in 1 ml of 75 % ethanol. The dried pellet was resuspended in 
distilled water (12 ?l) and the concentration was measured using a NanoDrop 
2000 spectrophotometer(PeqLab, Erlangen, DE). RNA of an OD260/280 nm 
>1.6 was used for reverse transcription. Total RNA was reverse transcribed with 
MuLV-RT (Fermentas, Burlington, Canada) using Oligo (dT)18 primers, 
according to the manufacturer’s protocol. 1-2 ?g RNA were mixed with 0,5 ?g 
Oligo (dT)18 primers and distilled water was added up to 11 ?l, incubated for 5 
minutes at 70°C and chilled on ice. To each reaction 4 ?l of 5x M-MuLV reverse 
transcriptase buffer, 1 mM dNTP mix, 20 U ribonuclease inhibitor, 200 U of 
RevertAid H Minus M-MuLV reverse transcriptase (all Fermentas) and distilled 
water to a final volume of 21 ?l were added. The mixture was incubated for 5 
minutes at 37°C, followed by incubation for 60 minutes at 42°C and 10 minutes 
at 70°C. Finally cDNA was diluted 1:2 prior to qPCR. cDNA was stored at -20°C 
until use.
Microarray analysis
Microarray analysis was performed by extracting total RNA from T cells
activated via plate-bound CD3/CD63 or CD3/CD28 antibodies in the presence 
and absence of ct-CD45Fc fusion proteins, respectively. T cell activation and 
cDNA preparation were performed as described above. cDNA from five human 
donors was pooled for each condition and subjected to microarray analysis 
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using an Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa 
Clara, CA). The analysis was performed in close collaboration with Novo 
Nordisk A/S (Bagsvaerd, Denmark).
Quantitative real-time PCR (qPCR)
Real-time PCR is a sensitive tool for the quantification of mRNA expression in 
different samples. Amplification is monitored via emission of a fluorescence 
signal corresponding to the increase of the PCR product. Detection is 
performed during the logarithmic phase of the PCR as soon as the fluorescence 
signal generated during the reaction significantly exceeds background noise
[79]. Common detection methods used include, for example, SYBR Green and
TaqMan detection. SYBR Green is a non-specific DNA-binding dye which only 
emits fluorescence when intercalating into DNA double-strands and thus 
corresponds to the increase of the (double-stranded) amplicon of the gene of 
interest. However, this method of detection also yields signals when binding to 
primer dimers and other non-specific PCR products. TaqMan probes are 
specific for the cDNA to be detected and are located within the sequence 
amplified by the primer pair. Probes harbour both a reporter dye and a 
quenching dye located at the 5’ and 3’ end of the probe, respectively. During the 
amplification polymerase 5’ exonuclease activity displaces the fluorescent dye 
from the quenching dye thus resulting in the release of a fluorescent signal [79].
Although absolute quantification using DNA standards encoding the sequence 
of interest would be possible expression differences are usually determined in a 
relative way. Housekeeping genes serve as internal standard to account for 
variations during RNA isolation and reverse transcription [84]. This way of 
quantification requires stable expression of this reference which must not be 
altered during any treatment of the cells during cell culture. However, many 
classical housekeeping genes have been shown to be actively regulated, 
especially in lymphocytes upon activation [85]. As regulation of housekeeping 
genes can vary considerably depending on the experimental setting it is crucial 
to validate several housekeeping genes for their suitability in the respective 
assay [86]. Thus, we analyzed four genes regarding stability of expression in 
our T cell activation/inhibition assays using ct-CD45 48 hours post activation.
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Among the genes tested, a distinct bias was detected for GAPDH which shows 
reduced upregulation in T cell activated in the presence of ct-CD45 compared to 
controls. The most stable genes in our assays were found to be CD3 epsilon 
?????????????-microglobulin which were barely altered by ct-CD45 treatment 
and were thus chosen as references for experiments.
Fig. 8: Validation of various housekeeping genes for normalization of real-time PCR 
experiments with ct-CD45-treated samples. 96-well plates were coated with anti-human and 
anti-mouse IgG antibodies, washed, incubated with anti-CD3, anti-CD3/CD63 or anti-CD3/CD28 
monoclonal antibodies in the presence or absence of ct-CD45/CTLA-4-Fc. T cells were plated 
and cultured for the indicated time. Total RNA was extracted, reverse transcribed using oligo-dT 
primers and quantitative realtime PCR was performed using intron-spanning primers. Mean 
values and standard deviation of duplicate determination is shown. Ct….crossing point (i.e. first 
significant increase above background fluorescence).
Quantitative real–time PCR (qPCR) was performed using the CFX 96 realtime-
PCR detection system (Bio-Rad Laboratories, Hercules, CA) using SYBR 
Green I (Bio-Rad). Detection was performed according to the manufacturer’s 
protocol. In all assays, cDNA was amplified using a standard program (2 
minutes at 50°C, 10 minutes at 95°C, 40 cycles of 15 sec at 95°C / 15 sec at 
60°C / 45 sec at 72°C). 
3.7. RNA interference
RNA interference is a cell intrinsic mechanism serving the degradation of 
foreign double-stranded RNA molecules such as found in many viruses. 
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Double-stranded RNA entering a cell is bound by protein complex with nuclease 
activity (Dicer) which cleaves the double-strand to fragments of 23 nucleotides
which are termed short-interfering RNAs (siRNAs). siRNAs are bound by the 
RISC complex which separates double-strands to base pair them with other 
double-stranded RNA molecules containing these sequences. As a result,
dsRNA is effectively degraded within a cell. The mechanism of RNA 
interference can be experimentally harnessed for the specific silencing of a 
gene of interest by introducing siRNA containing the desired sequence into a 
cell [48].
We transfected a mix of three different siRNA each of them targeted against 
SLFN12 and a control siRNA (Origene Technologies, Rockville, MD) at a final 
concentration of 10 nmol each into T cells.
The general transfection procedure was performed according to the 
manufaturer’s protocol. Amounts given are indicated for transfection in 96-well 
plates. Briefly, Lipofectamine 2000 (1µl per well) was diluted into 25 µl of OPTI-
MEM® medium (Life technologies, Carlsbad, CA) and incubated for 5 minutes at 
room temperature before it was combined with equal volumes of siRNA duplex 
diluted in OPTI-MEM. The mixture was incubated for 20 minutes at room 
temperature to allow complex formation. Complexes were then added to the 
cells, mixed by gently rocking the plate and incubated at 37°C, 5% CO2.
T cells were transfected 3 days after activation in 96-well plates coated with 
CD3/CD63 antibodies as described above. Cells were harvested 24 hours after 
transfection, washed and were allowed to rest for two days before restimulation 
with CD3/CD63 in the presence of fusion proteins for 3 days before measuring 
proliferation.
3.8. SDS-PAGE and Western Blot
SDS-PAGE
Sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) is a useful 
system to separate proteins according to their size. SDS is a strong detergent, 
having a hydrophobic tail (the lipid-like dodecyl part) and a negatively charged 
head group (the sulphate group). The dodecyl part interacts with hydrophobic 
amino acids in proteins. Since the 3D structure of most proteins depends on 
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interactions between hydrophobic amino acids in their core, the detergent 
destroys 3D structures, transforming what were globular proteins into linear 
molecules now coated with negatively charged SDS groups masking the actual 
charge of proteins. Thus, after boiling in the presence of SDS proteins are
unfolded and are separated according to their size. The reason why ?-
mercaptoethanol is usually included in the sample buffer is to reduce disulfide 
bonds within or between molecules, allowing molecules to adopt an extended 
monomeric form. 
Laemmli sample buffer (Biorad, Richmond, CA) containing 5% ß-
mercaptoethanol (Biorad) was used for preparation of SLFN12 fusion proteins 
and lysis of cells. Samples were boiled at 95 °C for 5 min before loading. 
Proteins were separated by electrophoresis on 10% SDS-polyacrylamide gels 
using the Hoefer Mighty Small system (Amersham, Little Chalfont, UK). As a 
running buffer 25 mM Tris base, 192 mM glycine, 0,1% SDS was used. A 
SeeBlue Plus2 prestained marker (Invitrogen) was used as a size marker.
Polyacrylamide gel composition
Reagent 10% separation gel 2% stacking gel
30% Acrylamide-solution 4 ml 440 µl
H2O 4,8 ml 2 ml
1,5 M Tris HCl pH 8,8 3 ml -
0,5 M Tris HCl pH 6,8 - 840 µl
10% SDS-solution 100 µl 35 µl
Ammoniumpersulfate (10%) 100 µl 35 µl
TEMED 8 µl 4 µl
Western Blotting
Western Blotting allows determining relative amounts of the protein present in 
different samples via the use of specific antibodies. Separated proteins are 
transferred to a membrane for detection. The membrane is incubated with a 
generic protein to bind to any remaining sticky places on the membrane and 
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therefore blocking unspecific antibody adherence on the membrane itself. A 
primary antibody is then added to the solution which is able to bind to its 
specific protein. A secondary antibody-enzyme conjugate, recognizing the 
primary antibody is added to bind and detect bound primary antibody.
Proteins that were separated by SDS-PAGE were blotted onto Immobilon-P
PVDF membranes (Millipore, Billerica, MA) using the Hoefer Semiphor TE77
system (Amersham, Buckinghamshire, UK) for 1 hour at 15 V. As a blotting 
buffer 25 mM Tris base, 192 mM glycine, 5% Methanol was used. Membranes 
were blocked with 5% dry milk / 0,05% Tween20 and incubated with primary 
antibody (1 ?g/ml) in the same solution. Bound Abs were detected using HRP-
conjugated goat antibodies to rabbit IgG (used at 1:2500; Dako) and 
chemiluminescence detection (SuperSignal West Femto Substrate, Thermo 
Fisher Scientific, Waltham, MA). Blots were developed on Kodak Biomax XAR 
films (Sigma-Aldrich).
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4. Results
4.1. ct-CD45 reduces cluster and blast formation of activated T cells
The cytoplasmic tail of CD45 was shown to be a potent inhibitor of T cells 
activated via CD3 or CD3/CD63 but not via CD3/CD28 [76, 77]. We found that 
this inhibition can even be achieved during strong activation as indicated by 
high levels of 3H-methyl thymidine uptake by T cells (Fig. 9) emphasizing the 
potent inhibitory action of ct-CD45.
Fig. 9: Inhibition of proliferation by ct-CD45 during strong T cell activation. 96-well plates 
were coated with anti-human and anti-mouse IgG antibodies, washed and incubated with 
antibodies targeted against (A) CD3, (B) CD3/CD63 and (C) CD3/CD28 in the presence or 
absence of ct-CD45. Proliferation was measured via 3H-methyl thymidine incorporation on day 3 
of activation. Data is displayed as counts per minute (cpm). Mean values +/- standard deviation 
(SD) of triplicate determination are indicated. One representative out of 4 independent 
experiments is shown.
The marked reduction in T cell proliferation exerted by the action of ct-CD45 is 
accompanied by distinct morphological differences between proliferating and 
growth-inhibited cells. Two main parameters characterizing T cell morphology 
upon activation in vitro were found to be drastically reduced. One typical feature 
most commonly observed is the formation of T cell blasts which is characterized 
by a profound increase in size of activated cells. As a second parameter 
clustering of neighbouring cells may occur depending on cell density as well as 
on the strength of activation. 
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Fig. 10: Changes of cell morphology caused by ct-CD45 during T cell activation. Plates 
were coated with anti-human and anti-mouse IgG antibodies, washed and incubated with anti-
CD3/CD63 in the presence or absence of ct-CD45. Activated T cells were observed via phase 
contrast microscopy on day 3 of activation. (A) T cells activated via CD3/CD63, (B) activated 
cells at 10-times higher magnification as indicated by red panels (C) T cells activated in the 
presence of ct-CD45 (D) Inhibited cells at higher magnification (10x).
The most dramatic effects caused by treatment with ct-CD45 on cell 
morphology were observed for T cells activated via antibodies against CD3 and 
CD63. Typically, cells receiving this type of stimulation show very little changes 
in cell morphology during the first 24 hours which may be due to a delayed 
onset of proliferation since CD63 expression is low on resting cells but is 
induced upon TCR triggering [37]. Usually, after 48-72 hours cells show 
dramatic increases in size (Fig. 10B). However, we found that activation in the 
presence of ct-CD45 most potently inhibits the formation of these T cell blasts 
(Fig. 10D). Additionally, CD3/CD63-activated T cells form clusters by day 3 (Fig. 
10A). Ct-CD45 treatment nearly seems to abrogate this effect (Fig. 10C). These 
distinct changes in morphology perfectly match the dramatic alterations in 
cytokine and cell surface activation marker expression reported previously [77].
A B
C D
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100 µm
100 µm
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The effects caused by ct-CD45 can also be readily visualized using flow 
cytometric analysis (Fig. 11). Both, forward scatter and side scatter referring to 
cellular size and intracellular complexity, respectively, are drastically reduced in 
CD3/CD63 stimulated T cells treated with ct-CD45 while T cells activated via 
CD3/CD28 are not susceptible towards this inhibitory signal.
Fig. 11: ct-CD45 reduces activation-induced increase in cellular size and complexity. T 
cells were activated via plate-bound CD3 and CD63 antibodies in the presence/absence of ct-
CD45 fusion proteins for four days. Cellular morphology was then analysed via flow cytometry.
One representative out of at least four independent experiments is shown.
4.2. T cell anergy induced by ct-CD45 can be partly reversed by IL-2 
and by IL-7
IL-2 has been described as a classical cytokine for the reversal of clonal T cell 
anergy [45]. Using this approach, IL-2 has been previously used to show that T 
cells rendered hyporesponsive by ct-CD45 can be partly restimulated in the 
presence of this growth factor [77]. IL-7 is a cytokine implicated in the 
homeostatic proliferation of naïve T cells and in memory T cell survival [80]. 
However, recently it was shown that IL-7 can be superior to IL-2 for the 
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expansion of tumour-specific CD4+ T cells ex vivo [81]. Thus, we investigated 
whether IL-7 can be used for a complete reversal of ct-CD45-induced T cell 
anergy.
Using a restimulation assay we activated T cells for 4 days via CD3/CD63 and 
CD3/CD28 in the presence and absence of ct-CD45 using CTLA-4 as a control 
fusion protein. The cells were then profusely washed and rested in fresh 
medium for 3 days before they were restimulated in the absence of fusion 
proteins but in the presence of either IL-2, IL-7 or medium control.
Fig. 12: ct-CD45-induced anergy of T cells can be partly reversed by both, IL-2 and IL-7. T 
cells primarily activated for 4 days via (A) CD3/CD63, (B) CD3/CD63 in the presence of ct-
CD45, (C) CD3/CD63 and CTLA-4 were restimulated in the absence of fusion proteins for 4 
days using CD3/63 supplemented with 10 U/ml IL-2, 10 ng/ml IL-7 or medium only. The same 
experimental procedure was performed for cells initially activated via (D) CD3/CD28, (E) 
CD3/CD28 and ct-CD45 and (F) CD3/CD28 including CTLA-4 as a control except using
CD3/CD28 for restimulation. Proliferation was measured by the uptake of 3H-methyl thymidine 
which was added to the culture on day 3. Data is displayed as counts per minute (cpm). Mean 
values +/- standard deviation (SD) of triplicate determination are indicated. One representative 
experiment out of four is shown.
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We found that IL-7 is capable of inducing proliferation in cells otherwise 
hyporesponsive to restimulation (Fig. 12B). It shows comparable effects to IL-2 
in enhancing the proliferation of control cells activated via CD3/CD63 (Fig 12A 
and 12C) but has a weaker effect on 3H-methyl thymidine incorporation of 
anergic T cells (Fig 12B and 12E) and cells restimulated via CD3/CD28 (Fig. 
12D and 12F). We also tested whether IL-2 and IL-7 might act synergistically in 
reversing the anergic state but could not find improved cell division compared to 
IL-2 and IL-7 alone (data not shown).
4.3. Molecular factors induced in ct-CD45-treated T cells are actively 
regulated during human T cell activation
The reduced T cell proliferation accompanied by reversible hyporesponsiveness 
to restimulation suggested an anergic state of ct-CD45 treated T cells. Aiming to 
identify molecular factors involved we performed microarray analysis of a pool 
of five donors comparing T cells activated via CD3/CD63 or CD3/CD28 
antibodies to T cells activated with the stimuli in the presence of plate-bound ct-
CD45. Surprisingly, we did not find elevated gene expression of anergy factors 
like diacylglycerol kinases, E3 ubiquitin ligases or transcription factors like 
EGR3 or Ikaros. Among the genes which were most strongly induced on the 
microarray were krüppel-like factor 2 and Schlafen family member 12 (SLFN12)
(data not shown). While KLF2 is a well established T cell quiescence factor [58], 
the function of SLFN12 in T cells has not been investigated before.
Since KLF2 is downregulated during T cell activation [58] we speculated that 
SLFN12 is similarly regulated. To test this hypothesis, we stimulated T cells with 
plate bound anti-CD3, anti-CD3 in the presence anti-CD28 or anti-CD3 and
CD63 antibodies for 6 hours, 12 hours, 24 hours and 48 hours. Total RNA was 
extracted from the cells at the indicated times, subjected to reverse transcription 
and mRNA expression levels were assessed using quantitative realtime PCR.
Upon activation SLFN12 was rapidly downregulated compared to unstimulated 
controls, remained low for up to 24 hours but was increasing again after 48 
hours (Fig. 13A). Compared to the classical T cell quiescence factor KLF2 (Fig 
13B) loss of SLFN12 after activation appears to be less pronounced. After 6 
hours expression levels are reduced by 50-65% while KLF2 mRNA shows 
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reduction between 80% and 90%. In contrast to SLFN12, KLF2 mRNA does not 
seem to increase again during a 48 hour time course.
Fig. 13: Regulation of SLFN12, KLF2 and classical anergy factors upon Tcell activation in 
the presence or absence of costimulation. T cells were activated via plate-bound antibodies 
for 6 hours, 12 hours, 24 hours and 48 hours. Total RNA was extracted, reverse transcribed 
using oligo-dT primers and quantitative realtime PCR was performed using mRNA-specific 
primers. (A) SLFN12, (B) KLF2, (C) EGR3 and (D) CBl-b mRNA. IFN-? (E) was used as a 
control for T cell activation. Data was normalized against untreated cells. Mean values +/-
standard deviation (SD) of duplicate determination of the reference gene are indicated. CD3E 
was used as a housekeeping gene. One representative experiment out of two is shown.
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Since both genes were indicated to be regulated in ct-CD45-induced T cell 
anergy we compared their expression to those of canonical anergy factors.
Both, EGR3 (Fig. 13C) and CBL-b (Fig. 13D) appear to be upregulated in the
presence of an activation stimulus and thus show inverse regulation to 
quiescence genes. As reported before [50], EGR3 was strongly transcribed very 
early in T cell activation and shows elevated expression levels for CD3 
stimulation in the absence of costimulation (Fig 13C) which is a classical way to 
induce anergy in T cells [46]. Compared to EGR3, CBL-b mRNA shows only low 
upregulation upon T cell activation. CBL-b levels were only found to be 
significantly increased in CD3 stimulated cells after 24 hours (Fig. 13D). 
However, it was shown that CBL-b is proteolytically degraded upon T cell 
????????????????????-dependent manner [83] suggesting that its regulation might 
be more prominent on the protein level.
CD3 stimulation without costimulation did not seem to trigger significant 
induction of both SLFN12 and KLF2 indicating that both factors are presumably 
not involved in canonical T cell anergy.
4.4. SLFN12 is not regulated during the activation of monocyte-
derived dendritic cells via LPS
Since the down-regulation of SLFN12 during the activation of human T cells 
represents a novel finding we investigated whether this factor was regulated in 
a similar manner by the activation of other immune cells. Recently, it was 
reported that SLFN12 was upregulated during the activation of human 
monocyte-derived macrophages via LPS [70].  Since this mechanism might be 
similar in other immune cells challenged with LPS the expression of SLFN12 
and of other members of the human SLFN family was tested in monocyte-
derived dendritic cells (mDCs).
Reproducible expression of all SLFN family members except SLFN14 (data not 
shown) was obtained for this cell type in vitro. Upon LPS challenge two SLFN 
family members were found to be substantially regulated in mDCs. SLFN5 was 
strongly upregulated 2h after addition of LPS to the culture medium reaching its 
maximum induction after 5 hours to decline again after 24 hours (Fig. 14A). 
Conversely, SLFN11 was downregulated by about 60% 2 hours after LPS 
challenge and remained at this level 22 hours later (Fig. 14B). We did not find 
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substantial changes in the expression of SLFN12 (Fig. 14C), SLFN12L (Fig. 
14D) and SLFN13 (Fig. 14E) mRNA expression suggesting that these 
Schlafens are presumably not regulated by LPS-mediated TLR4 signalling. 
These results also indicate that the regulation of SLFN12 via LPS as reported 
by van Zuylen et al. [70] is probably cell type-specific and does not represent a 
universal mechanism within the human immune system.
Fig. 14: SLFN5 and SLFN11 but not other SLFNs are regulated by LPS challenge of
mDCs. Monocytes were differentiated via IL-4 and GM-CSF to dendritic cells. mDCs were 
stimulated on day 7 of differentiation with 1 µg/ml of LPS. RNA was extracted from the cells at 
the indicated times and reverse transcribed. (A) SLFN5, (B) SLFN11, (C) SLFN12, (D) 
SLFN12L, (E) SLFN13 mRNA expression was quantified via qPCR. Mean values +/- standard 
deviation of two independent experiments are shown.
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4.5. Expression of Schlafen family members in human T cells and in 
human cell lines
The Schlafen gene family has been implicated in cellular growth control by 
several studies carried out in the murine system [61, 62, 65, 66]. Thus, we 
asked ourselves whether human Schlafens might exert a similar role in immune 
cells as well as in other tissues. In order to obtain a first indication for their 
involvement in cellular growth we compared SLFN gene expression in naïve T 
cells to continuously dividing cells lines. The human T cell leukaemia line Jurkat 
[87] and SK-N-SH, a human neuroblastoma cell line [88] were chosen as 
models for this purpose. In addition to the six members of the human SLFN 
family we also tested for KLF2 and Cyclin E1 expression serving as controls for 
highly and lowly expressed genes in resting T cells, respectively.
While cyclin E1 is roughly 5 to 8 fold increased in the cell lines compared to 
naïve T cells, KLF2 is considerably higher expressed in T cells compared to 
both cell lines (Fig. 15). The same holds true for most Schlafen family members.
Expression differences observed for T cells vs. the neuroblastoma cell line SK-
N-SH range from about 2x101 to 104, with the least differences observed for 
SLFN12 and the highest for SLFN5 and SLFN12-like (SLFN12L). The 
expression profile for T cells vs. Jurkat cells looked slightly different. While the 
biggest differences were observed for SLFN12L (~104-fold), SLFN11 was even 
found to be slightly increased in Jurkat cells questioning a possible role for this 
Schlafen family member in T cell growth control. SLFN12 was observed to be 
robustly expressed in naïve T cells with about 350-fold higher expression in 
these quiescent cells relative to proliferating Jurkat cells.
4.6. SLFN12 and KLF2 mRNA are induced by ct-CD45 in T cells
Microarray analysis is valuable tool for genome wide screens of gene 
expression. However, its accuracy and reproducibility is limited, especially for 
low abundance transcripts [92]. Thus, it was essential to validate our results 
obtained when analysing gene expression of T cells activated in the presence of 
ct-CD45. Testing SLFN12 and KLF2 expression 48 hours after activation we 
indeed found upregulation of both mRNAs in peripheral T cells which were 
anergized by ct-CD45. Regulation of SLFN12 closely correlated with the degree 
of inhibition observed for T cells activated with three different stimuli. Its 
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strongest induction was observed for T cells activated via CD3 and CD63 
monoclonal antibodies (Fig. 16B), followed by CD3 stimulation alone (Fig. 16A). 
Substantial upregulation of SLFN12 was also obtained for CD3/CD28 
stimulation (Fig. 16C) even though in our hands proliferation of T cells receiving 
these stimuli was never found to be impaired.
Regulation of KLF2 was more subtle with less strong induction (Fig 16D-F). 
However, we also obtained slightly increased KLF2 expression for ct-CD45 
treated T cells in the context of a CD3/CD28 stimulus (Fig. 16F) indicating an 
involvement of this gene in the anergic state induced.
Fig. 15: Expression profiles of Schlafen family members in T cells relative to 
continuously dividing cell lines. Cryopreserved naïve human T cells were thawed from liquid 
nitrogen stocks and were lysed without prior culturing. Cell lines were harvested the day after 
medium renewal to ensure logarithmic growth. Adherent cells (SK-N-SH) were directly lysed in 
the tissue culture plate without prior detachment with trypsin. Total RNA was isolated and 
mRNA was reverse transcribed using oligo-dTTT primers. Quantitative realtime-PCR was 
performed using specific intron-spanning primers for the genes indicated. Gene expression was 
calculated using CD3E (T cells vs. Jurkat cells) and beta-Actin (T cells vs. SK-N-SH) as 
reference genes. Relative expression was normalized to the respective cell line.
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Fig. 16: SLFN12 and KLF2 are both induced in T cells activated in the presence of ct-
CD45. 96-well plates were coated with anti-human and anti-mouse IgG antibodies, washed, 
incubated with anti-CD3, anti-CD3/CD63 or anti-CD3/CD28 monoclonal antibodies in the 
presence or absence of ct-CD45. CTLA-4-Fc was used as a control fusion protein. Total RNA 
was isolated, reverse transcribed using oligo-dTTT primers and subjected to quantitative 
realtime PCR. SLFN12 regulation in the presence/absence of ct-CD45 and CTLA-4 for (A) CD3, 
(B) CD3/CD63, (C) CD3/CD28 stimulation. KLF2 regulation towards the same stimuli for (D) 
CD3, (E) CD3/CD63, (F) CD3/CD28. Beta2-microglobulin was used for reference. Data is 
displayed as percent of stimulation without fusion protein +/- standard deviation of duplicate 
measurement of the reference gene. One representative experiment out of two is shown.
4.7. Confirmation of SLFN12 expression on the protein level – lack of 
reliable antibodies
In order to have another line of evidence for SLFN12 expression we tried to 
detect the mature protein in cell lysates. We purchased two polyclonal 
antibodies specific for the N-terminus and C-terminus of SLFN12 as indicated in 
Fig. 17A. Using a recombinant SLFN12-GST fusion protein as a positive control 
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we found strong reaction of both antibodies with the fusion protein. As the latter 
represents a truncated form of SLFN12 which lacks the N-terminal end of the 
native protein this result is somewhat surprising. When probing cell lysates of T 
cells and the SK-N-SH cell line both antibodies reacted distinctly with both cell 
types. However, when probing BW 5417, a murine thymoma cell line, which 
should serve as a negative control strong bands were obtained with both 
antibodies at approximately the same migration distance as observed for T cells 
and SK-N-SH (Fig. 17A). We performed quantitative real-time PCR testing 
SLFN12 expression in the respective cell types and could detect SLFN12 
mRNA in both T cells and the SK-N-SH cell lines but not in BW 5417 (Fig. 17B). 
Thus, we have to conclude that bands observed for cell lysates do not 
correspond to SLFN12 but are rather unspecific signals. Concentration of our 
protein of interest and/or antibody affinity might be too low to enable detection. 
4.8. Kinetics of SLFN12 induction in peripheral blood T cells
Since inhibition of T cells by ct-CD45 might occur from the beginning, we 
investigated the regulation of SLFN12 and of KLF2 during the first 24 hours post 
activation in the presence of the respective fusion protein. Using CD3/CD63 
antibodies as a stimulus we activated human T cells for 6 hours, 12 hours and 
24 hours and isolated RNA at the given times.
We found that SLFN12 seems to be induced very early after activation in the 
presence of ct-CD45 (Fig. 18A) although we cannot exclude that this elevated 
expression is due to mRNA stabilization rather than enhanced transcription. 
However, although SLFN12 levels in ct-CD45 treated cells seem to decrease 
compared to controls 12 hours post activation, they seem to recover after 24 
hours suggesting an oscillating expression pattern. Interestingly, we did not 
observe KLF2 induction for peripheral T cells treated with ct-CD45 during the 
first 24 hours of induction (Fig. 18B) indicating that its induction might only occur 
after this period.
The transcription factor EGR3 (Fig. 18C) was slightly induced by ct-CD45 
treatment but only after 12 hours of activation. CBL-b (Fig. 18D) was barely 
affected throughout the time course showing only weak induction after 24 hours. 
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Fig. 17: Reaction of two polyclonal SLFN12 antibodies with a SLFN12 fusion protein and 
cell lysates. (A) Western Blotting was performed using an N-terminal and a C-terminal SLFN12 
antibody. The SLFN12-GST fusion protein corresponds to amino acids 230-578 of the full length 
(578 aa, 67kDa) protein. 2µg of fusion protein and total protein of 500 000 cells were loaded per 
lane. Arrows and marked regions show the specificity of both antibodies within full-length 
SLFN12. (B) SLFN12 expression as determined by qPCR. One representative experiment out 
of three is shown.
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4.9. Kinetics of SLFN family regulation by ct-CD45 in peripheral T 
cells
All proteins of the Schlafen family share common sequence motifs [65-67] 
suggesting potential redundancy in molecular function. Thus, we speculated 
that other Schlafens might be similarly regulated upon ct-CD45 binding to 
human T cells. Addressing this question, we analyzed the expression of other 
SLFN family members comparing their induction over a 24 hour timecourse to 
that observed for SLFN12. Indeed, we found intriguing similarities in the 
regulation of most human SLFN family members in response to ct-CD45. 
SLFN12-like (Fig. 19C) shares the strongest resemblance to SLFN12 (Fig. 18A) 
as we found strong induction after 6 hours, accompanied by a decline by hour 
12 to be reinduced after 24 hours. This expression pattern mirrors regulation of 
SLFN12 over this time course (Fig. 18A). Other SLFNs including SLFN5 (Fig. 
19A) and SLFN13 (Fig. 19D) were induced by ct-CD45 after 6 hours to decline 
after 12 hours. However, unlike SLFN12 and SLFN12-like they were not found 
to be reexpressed after 24 hours. 
SLFN11 (Fig. 19B) and SLFN14 (Fig. 19E) were barely affected by ct-CD45 
treatment although we could find substantial downregulation of the latter 24 
hours after activation compared to non-activated T cells. We found little 
regulation of SLFN11 and SLFN13 by activating stimuli, whereas SLFN5 and 
SLFN12L were downregulated by 24 hours.
4.10. Exogenous IL-2 reduces SLFN12 mRNA levels in ct-CD45 
treated T cells
Based on the observation that IL-2 partly reverses the ct-CD45-induced 
hyporesponsive state in human T cells it was investigated whether exogenous 
IL-2 alters expression SLFN12 and KLF2 in the induction phase of this state.
Indeed, we found that addition of IL-2 has a dramatic effect on SLFN12 
expression. SLFN12 was drastically reduced regardless of the nature of the 
activating stimulus leading to a decrease even below the levels of the untreated 
controls (Fig. 20A-C). We did not obtain the same results for KLF2. Although 
KLF2 was reduced by CD3 stimulation alone (Fig 20D), a reduction of mRNA 
levels was not obtained neither for CD63 (Fig. 20E) nor for CD28 (Fig. 20F) 
costimulation.
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Fig. 18: Kinetics of SLFN12 induction in human peripheral blood T cells. 96-well plates 
were coated with anti-human and anti-mouse IgG, washed and incubated with anti-CD3/CD63 
in the presence or absence of ct-CD45 and CTLA-4 or were left untreated. T cells were 
activated for 6 hours, 12 hours and 24 hours. Total RNA was extracted and was reverse 
transcribed using oligo-dTTT primers. Regulation of (A) SLFN12, (B) KLF2, (C) EGR3, and (D) 
CBL-b was determined using quantitative realtime PCR. Data was normalized against untreated 
T cells. Mean values +/- standard deviation (SD) of duplicate determination of the reference 
gene are indicated. CD3E was used as a housekeeping gene. One representative out of two 
independent experiments is shown.
Results
78
Fig. 19: Regulation of other SLFN family members by ct-CD45. T cells were activated for 24 
hours via CD3/63 in the presence or absence of ct-CD45/CTLA-4. Harvests were performed 
after 6 hours, 12 hours and 24 hours. Total RNA was extracted and was reverse transcribed 
using oligo-dTTT primers. Regulation of (A) SLFN5, (B) SLFN11, (C) SLFN12-like, (D) SLFN13 
and (E) SLFN14 was determined using quantitative realtime PCR. Data was normalized against
untreated T cells. Mean values +/- standard deviation (SD) of duplicate determination of the 
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reference gene are indicated. CD3E was used as a housekeeping gene. One out of two
independent experiments is shown.
Fig. 20: Exogenous IL-2 reduces levels of SLFN12 but not of KLF2 mRNA in T cells 
treated with ct-CD45. 96 well plates were coated with anti-human and anti-mouse IgG 
antibodies, washed, incubated with anti-CD3, anti-CD3/CD63 or anti-CD3/CD28 monoclonal 
antibodies in the presence or absence of ct-CD45 or in the presence of ct-CD45 including 10 
U/ml of IL-2. Total RNA was isolated, reverse transcribed using oligo-dTTT primers. Quantitative 
realtime PCR was performed using primers specific for SLFN12 and KLF2. (A-C) SLFN12 
regulation in the presence of ct-CD45 and IL-2 for different activation stimuli. (D-F) KLF2 
regulation upon addition of IL-2. Beta-2-microglobulin was used as a reference. Data is 
displayed as percent of stimulation without fusion protein +/- standard deviation of duplicate 
measurement of the reference gene. One representative experiment out of two is shown.
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4.11. Kinetics of SLFN12 induction in Cord Blood T cells
Since human cord blood T cells could not be inhibited in the presence of ct-
CD45 we investigated whether differences in the induction of SLFN12 might 
provide an explanation for this phenomenon. As done before with peripheral 
blood T cells we determined the kinetics within a 24 hour time course using 
CD3/CD63 stimulation as a model.
As observed before, SLFN12 was downregulated upon T cell activation already 
after six hours, remained low after 12 hours and seemed to increase again in 
after 24 hours (Fig. 21A). Treatment with ct-CD45 does not seem to alter 
SLFN12 expression during the first hours but then rapidly peaks after 12 hours 
to reach expression levels of unstimulated (i.e. resting) T cells. By 24 hours 
SLFN12 expression declines again nearly reaching the levels of activated 
controls.
KLF2 seems to be induced in a similar manner. However, KLF2 mRNA levels 
upon ct-CD45 treatment are already higher after 6 hours (Fig. 21B) but also 
peak after 12 hours to decrease again by 24 hours.
As observed for peripheral T cells, EGR3 (Fig. 21C) and CBL-b (Fig. 21D) are 
not strongly regulated by treatment with ct-CD45. EGR3 appears to be slightly 
increased after 24 hours but was not found to be regulated before this time. No 
significant expression changes throughout the observed time course were 
detected for CBl-b.
4.12. Expression kinetics of other SLFN family members induced by 
ct-CD45
Since other members of the human SLFN family were partly regulated in a 
similar way to SLFN12 in T cells treated with ct-CD45 we also tested their 
expression kinetics during a 24 hour time course in cord blood T cells.
Again, striking similarities were found. Generally, there was a transient 
downregulation of SLFN mRNA by 12 hours which nearly returned to the level 
of the unstimulated control by 24 hours except for SLFN5 which remained low. 
In the presence of ct-CD45 there was no significant difference to activated 
controls after 6 hours. Similar to SLFN12 (Fig. 21A) other Schlafen family 
members including SLFN5 (Fig. 22A), SLFN11 (Fig. 22B), SLFN12-like (Fig. 
22C) and SLFN13 (Fig. 22D) were induced after 12 hours but decreased by 24 
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hours. While SLFN11 expression only subtly changed during T cell activation as 
well by ct-CD45 treatment SLFN14 (Fig. 22E) was not inducible at all by ct-
CD45 in cord blood T cells. Although all Schlafen family members were 
decreased during the first hours of culture regardless of stimulus SLFN14 and 
SLFN13 were most severely affected and never returned to their initial levels.
Fig. 21: Kinetics of SLFN12 induction in human cord blood T cells. Plates were coated with 
anti-human and anti-mouse IgG antibodies, washed, incubated with anti-CD3/CD63 in the 
presence or absence of ct-CD45 and CTLA-4 or were mock treated. Coord blood T cells were 
activated for 6 hours, 12 hours and 24 hours. Total RNA was extracted reverse transcribing 
mRNA into cDNA. Regulation of (A) SLFN12, (B) KLF2, (C) EGR3, and (D) CBL-b was 
determined using quantitative realtime PCR. Mean values +/- standard deviation (SD) of 
duplicate determination of the reference gene are indicated. CD3E was used as a 
housekeeping gene.
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Fig. 22: Expression of other human SLFN family members during activation of human 
cord blood T cells. Plates were coated with anti-human and anti-mouse IgG antibodies, 
washed incubated with anti-CD3/CD63 in the presence or absence of ct-CD45 and CTLA-4 or 
were mock treated. Coord blood T cells were activated for 6 hours, 12 hours and 24 hours. 
Total RNA was extracted and reverse transcribed into cDNA. Regulation of (A) SLFN5, (B) 
SLFN11, (C) SLFN12-like, (D) SLFN13, (E) SLFN14 was analysed using quantitative realtime 
PCR. Mean values +/- standard deviation (SD) of duplicate determination of the reference gene 
are indicated. CD3E was used as a housekeeping gene.
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4.13. Inhibition by ct-CD45 is accompanied by a reduction in cyclin 
D1 mRNA levels
Growth regulation by some members of the Schlafen family in the mouse has 
been shown to occur via specific inhibition of cyclin D1 [62] although these 
findings have not been left unchallenged [63]. Hypothesizing that SLFN12 might 
exert its action via a similar mechanism we investigated the expression of 
selected D- and E-type cyclins and their respective kinases.
Again we relied on CD3/CD63 activation over a 24 hour course as a model. We 
did not find expression of cyclin-dependent kinases (CDK) 2 and 4 (Fig. 23A-B) 
impaired in T cells provided with ct-CD45 during activation indicating that kinase 
activity rather than kinase protein levels must be affected. However, when 
looking at cyclin expression patterns we found substantial inhibition of cyclin D1 
(Fig. 23C) expression although this decrease in mRNA levels was only 
detectable after 24 hours. Detection of cyclin D1 mRNA in human T 
lymphocytes is of special interest since it was reported not to be expressed in 
this cell type [89]. A plausible explanation for these diverging results might lie in 
the advances of PCR technology since the publication of the prior finding.
We did not obtain reproducible inhibition of cyclin D2 mRNA (Fig. 23D) although 
this cyclin is induced early after T cell activation [89]. A similar result was 
obtained for the E-type cyclin E1 (Fig. 23E). 
p27kip1 has been described as specific inhibitor of CDK2 activity and as a 
potential anergy factor [55]. Thus, we investigated whether it acts in a similar 
manner in ct-CD45-induced T cell anergy. However, we could not find 
prolonged and substantial induction of p27kip1 (Fig. 23F) during the time course 
indicating that it might not be causative factor for the distinct hyporesponsive 
state of T cells anergized via ct-CD45.
4.14. Cyclin gene expression is also reduced in cord blood T cells
We investigated whether induction of cyclins is also impaired in cord blood T 
cells, despite lack of reproducible inhibition of proliferation [77]. However, 
cytokine levels are similarly reduced as in peripheral T cells suggesting some 
effect of ct-CD45 binding [77].
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Fig. 23: Regulation of cyclins and cyclin-dependent kinases by ct-CD45. Plates were 
coated with anti-human and anti-mouse IgG antibodies, washed, incubated with anti-CD3/CD63 
in the presence or absence of ct-CD45 and CTLA-4 or were mock treated. Peripheral T cells 
were activated for 6 hours, 12 hours and 24 hours. Total RNA was extracted reverse 
transcribing mRNA into cDNA. Regulation of (A) CDK2, (B) CDK4, (C) Cyclin D1, (D) Cyclin D2 
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and (E) Cyclin E1 and (F) p27kip1 was determined using quantitative realtime PCR. Mean values 
+/- standard deviation (SD) of duplicate determination of the reference gene are indicated. 
CD3E was used as a housekeeping gene. One representative out of two experiments 
performed is shown.
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Fig. 24: Regulation of cyclins and cyclin-dependent kinases in cord blood T cells. Plates 
were coated with anti-human and anti-mouse IgG antibodies, washed, incubated with anti-
CD3/CD63 in the presence or absence of ct-CD45 and CTLA-4 or were mock treated. T cells 
from human umbilical cord blood were activated for 6 hours, 12 hours and 24 hours. Total RNA 
was extracted reverse transcribing mRNA into cDNA. Regulation of (A) CDK2, (B) CDK4, (C) 
Cyclin D1, (D) Cyclin D2 and (D) Cyclin E1 and p27kip1 was determined using quantitative 
realtime PCR. Mean values +/- standard deviation (SD) of duplicate determination of the 
reference gene are indicated. CD3E was used as a housekeeping gene.
Nevertheless, we did not expect to see effects on cyclin levels which should be 
associated with altered CDK activity and subsequently impaired cell cycle 
progression. We were quite surprised to find that even cord blood T cells 
display reduction in cyclin D1 (Fig. 24C) as well as in cyclin D2 expression (Fig. 
24D). As observed before for peripheral T cells, induction of cyclin E1 was 
unaltered (Fig. 24E). Similarly, expression of cyclin-dependent kinases CDK2 
(Fig. 24A) and CDK4 (Fig. 24B) was barely affected. The CDK inhibitor p27kip1
was not found to be regulated by ct-CD45 during the first 12 hours (Fig. 24F). 
However, unlike in peripheral T cells a slight increase in p27kip1expression was 
obtained after 24 hours.
4.15. Transfection of a SLFN12 siRNA reduces inhibition of T cell 
proliferation
As our results strongly suggested a role for SLFN12 in the inhibition of 
peripheral T cell proliferation we investigated whether loss of SLFN12 might 
prevent this inhibition observed. Applying a siRNA-mediated knockdown 
approach, we hoped to achieve sufficient reduction of SLFN12 mRNA to obtain 
a phenotype. The major obstacle for such an approach lies in the lack of 
efficient non-viral transfection protocols [90]. Using LipofectamineTM 2000 which 
is a cationic lipid-based transfection reagent [91] we transfected human T cells 
which were pre-activated via plate-bound CD3 and CD63 antibodies for three 
days with a mix of three different SLFN12 siRNAs at a concentration of 10 nmol 
per duplex. Transfected T cells were harvested 24 hours after transfection and 
rested for 2 days in fresh medium until they were restimulated with CD3/CD63 
in the presence or absence of ct-CD45 fusion proteins. Proliferation of re-
stimulated T cells was tested using 3H-methyl thymidine incorporation as a 
read-out. Slightly increased proliferation was observed for ct-CD45-treated T 
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cells after transfection with the SLFN12 siRNA mix compared to scrambled and 
transfection reagent controls (Fig. 25A). 
Fig. 25: Transfection of a SLFN12 siRNA mix enhances proliferation of ct-CD45 treated T 
cells. T cells were activated via plate-bound CD3/CD63 antibodies for four days in a 96-well 
plate. Transfection of scrambled control and a mix of three SLFN12 siRNAs (10nmol each) were 
transfected using LipofectamineTM 2000 on day 3. Cells were harvested on day four, washed 
and let rest for two days until they were restimulated with CD3/CD63 and plate-bound fusion 
proteins. 3H-methyl thymidine was added on day 3 of restimulation and incorporation was 
measured 18 hours later. Proliferation of transfected T cells after restimulation is displayed 
relative (%) to inhibition. Data shown are mean values +/- SD of triplicates. 
4.16. ct-CD45 shows blockable binding to a Bw clone expressing 
PRAT4A
A screen of a human T cell cDNA library expressed in the Bw 5417 cell line 
revealed the protein associated with Toll-like receptor 4 A (PRAT4A) as a 
potential receptor candidate for ct-CD45 [77]. Although a siRNA knock-down of 
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PRAT4A in the PRAT4A-expressing BW clone 1C8 could reduce binding of ct-
CD45 by about 50%, a direct blockade of ct-CD45 via antibodies could not be 
shown [77]. Initially, PRAT4A was described as a protein regulating the cell 
surface expression of TLR4 [78] as well as of other TLRs which resides in the 
endoplasmic reticulum [82]. However, PRAT4A seems to be expressed at low 
levels at the cell surface of activated T cells [77].
We tested whether binding of ct-CD45 can be blocked by a PRAT4A antibody.
Bw clone 1C8 was preincubated with a polyclonal rabbit anti-PRAT4A antibody 
or mock-treated before addition of ct-CD45 fusion proteins. Flow cytometric 
analysis revealed markedly reduced binding of ct-CD45 to the cell line upon 
PRAT4A blockade suggesting interaction between the two molecules (Fig. 26).
Fig. 26: ct-CD45 binding to a PRAT4A-overexpressing BW clone can be blocked by a PRAT4A 
antibody. The BW clone 1C8 was stained with a ct-CD45-Fc fusion protein with or without prior 
incubation with a polyclonal rabbit anti-murine PRAT4A antibody. CTLA-4-Fc was used as a non-
binding control. A phycoerythrin-labelled antibody specific for the Fc fragment of human IgG was used 
for detection via flow cytometry. The shaded histogram represents ct-CD45 binding to the cell line;
dotted lines stand for preincubation with a PRAT4A antibody prior to addition of ct-CD45. Full lines are
the non-binding  control.
Discussion
89
5. Discussion
The study by Kirchberger et al. [76] suggested that the alternative cleavage of 
the well characterized tyrosine phosphatase CD45 [71] gives rise to a product 
negatively regulating the proliferation of human T cells. However, the distinct
molecular pattern governing this state remained unidentified. It was already 
known that this reduction in proliferation was not due to cell death as affected 
cells were still alive. As demonstrated in the present work, one remarkable 
feature of ct-CD45-inhibited T cells is the inability of lymphoblast formation, 
characterized by increase in cellular size (Fig. 10). Instead, the cells remained 
relatively small which was accompanied by a lack of T cell activation markers as 
shown before [77]. Another finding was that T cells treated with ct-CD45 are 
hyporesponsive to restimulation but can be partly restimulated in the presence 
of exogenous IL-2 [77]. Since microarray analysis indicated downregulation of 
the IL-2 receptor in ct-CD45-treated lymphocytes, we concluded that 
restimulation via this classical growth factor might probably be inefficient due to 
a lack of IL-2 binding. Thus, it was further investigated whether alternative 
factors reported for their cabability of promoting T cell expansion in vitro might 
better serve our purpose. IL-7 is a cytokine which was originally implicated in 
maintenance of memory cell homeostasis [80] However, a recent study showed 
that IL-7 was more efficient than IL-2 in ex vivo expansion of tumour-specific 
CD4+ T cells [81]. Indeed, it was found that IL-7 aids in restimulation of T cells 
anergized via ct-CD45 (Fig. 12). Nevertheless, it displayed lower efficiency than 
IL-2 indicating that IL-7 cannot act as a full growth factor in this distinct anergic 
state.
To our surprise, the microarray data did not show induction of established 
molecules involved in anergy. Instead, SLFN12 and KLF2 were most strongly 
transcribed which was confirmed via quantitative real-time PCR (Fig. 16). While 
KLF2 represents a well characterized factor involved in T cell quiescence [60] 
little was known to date about SLFN12. 
Most research related to the Schlafen gene family has been carried out in the 
murine system. Initial studies associated this family with the regulation of 
lymphocyte development and growth control [61]. The inhibitory roles of 
Schlafen family members appeared to occur very early in the cell cycle before 
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G1 to S phase transition [61] and was molecularly characterized to occur at the 
transcriptional level via inhibition of cyclin D1 promoter activity at least in the 
case of prototypic Slfn1 [62]. The most striking finding was by Berger et al. [66] 
demonstrating a non-redundant function of murine Slfn2 in lymphocyte 
quiescence, again indirectly providing evidence for a growth regulatory role of 
SLFNs. The human SLFN family bears little orthology to the murine slfns. 
SLFN12 is exclusively expressed in primate species [99]. Compared to 
SLFN12, Slfn2 [66] and Slfn3 are mostly similar. However, a BLAST search 
using SLFN12 mRNA as a query (NM_018042.3) indicates low overall similarity 
implying some distinctiveness in function. Nevertheless, our results with human 
T cells inhibited by ct-CD45 suggests a role for SLFN12 in the quiescent state 
and in T cell anergy similar to other factors exerting dual roles such as Tob or 
Ikaros [51]. KLF2 is another classical quiescence factor [60] but has hitherto 
never been reported to be highly expressed in anergic T cells. While an anti-
proliferative role for KLF2 has been established via overexpression experiments 
in the T cell leukaemia line Jurkat [93] such a role has still to be shown for 
SLFN12. Nonetheless, the expression of these quiescence factors in activated 
T cells retaining their small cellular size while being hyporesponsive to 
restimulation suggests the repertoire of functional plasticity of T cell 
differentiation states extended. It is tempting to speculate that these combined 
features represent another functional state for T cells - “quiescent anergy”. 
Quiescent-anergic lymphocytes share features with anergic T cells regarding 
their hyporesponsiveness to activation while retaining small cellular size similar 
to cellular quiescence (Table 2).
Expression profiling of naive T cells versus Jurkat cells and the neuroblastoma 
cell line SK-N-SH showed considerably lower expression not only of SLFN12 
and KLF2 but of most other SLFN family members in both cell lines (Fig. 15). 
This indicates that high expression of these genes would not be beneficial for 
survival or growth of continuously dividing cell lines. We also assessed SLFN12 
and KLF2 regulation during the first few hours upon T cell activation showing 
that both factors are downregulated already after 6 hours (Fig. 13). However, 
while KLF2 transcription is sustainably decreased, SLFN12 downregulation 
seems to be transient. After 24 hours SLFN12 mRNA levels start to rise in 
activated cells and have nearly reached the levels of unstimulated controls after 
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48 hours. This pattern raises a question whether a factor only transiently lost 
upon activation can have an essential role in proliferation. Nevertheless, this 
supports the role of SLFN12 during earlier stages of T cell activation probably 
negatively regulating cell cycle entry from the G0 phase. 
We did not find any evidence for an involvement of SLFN12 or KLF2 in the 
induction of canonical T cell anergy. Altered transcription of any of these two 
factors was not detected for TCR stimulation in the absence of costimulation 
whereas EGR3 was found to be substantially upregulated. 
phenotype
quiescent 
lymphocytes
activated 
lymphocytes
anergic
lymphocytes
„quiescent-
anergic“ 
lymphocytes
cell size small large large small
rate of protein 
synthesis low high low low
response to 
activation proliferation
expansion or 
apoptosis
none or 
apoptosis none
Table 2: T cell differentiation states extended. The morphological and functional features as 
well their gene expression profile suggest a novel functional state for T cells binding ct-CD45 
sharing features of both, quiescent and anergic lymphocytes Table adapted and modified from 
Yusuf and Fruman [58].
Additionally, it was investigated whether SLFN12 is regulated in other immune 
cells upon activation. Based on the observation of van Zuylen et al. [70] 
showing upregulation of SLFN12 during LPS stimulation of human monocyte-
derived macrophages we tested the expression of SLFN12 and other SLFN 
family members during the LPS challenge of human monocyte-derived dendritic 
cells. While little to no regulation was observed for SLFN12, SLFN12L, SLFN13 
and SLFN14, SLFN5 was found to be substantially increased peaking 5 hours 
after LPS challenge. Conversely, SLFN11 was sustainably downregulated 
during a 24 hour time course (Fig. 14). These results suggest a possible role for 
these two SLFNs but not of other SLFN family members during the LPS-
induced maturation of human dendritic cells. The regulation of SLFN12 as 
shown for macrophages might possibly be specific for this cell-type.
Having confirmed SLFN12 and KLF2 expression via qPCR 48 hours post 
activation we also hoped to confirm this expression on the protein level. 
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Unfortunately reliable antibodies serving this purpose are not available. 
Although reactivity with a SLFN12 fusion protein and human cell lysates could 
be shown, substantial differences in the molecular weights of detected bands 
were found for two different SLFN12 antibodies. Both antibodies also displayed 
strong reaction with cell lysates of the murine Bw 5417 cell line (Fig. 17). The 
latter observation suggests that the bands observed might be cross-reactions to 
other ubiquitously expressed proteins. As SLFN12 mRNA appears to be 
expressed at moderate to low levels it has to be concluded that the protein 
amount in the cell lysates is presumably below the limit of the detection for a 
western blot.
The kinetics of SLFN12 induction were observed over a shorter 24-hour time 
course and it was found that SLFN12 is induced very early in ct-CD45-treated T 
cells reaching its maximum after 6 hours (Fig. 18). We cannot exclude that this 
early upregulation is a result of mRNA stabilization rather than being an active 
transcriptional process. However, SLFN12 seems to be re-expressed 24 hours 
post activation suggesting an oscillating expression pattern. Surprisingly, 
elevated expression of KLF2 within the first 24 hours could not be shown, 
posing the question whether KLF2 might be important for the induction phase of 
anergy at all. Expression at a later time might just reflect a reduction in cell 
cycle progression. During the observed time course slight induction of EGR3 
and of CBL-b was obtained after 12 hours and 24 hours, respectively. Since 
molecular targets of SLFN12 are unknown it cannot be excluded that both 
genes are transcribed as a result of SLFN12 expression. However, this 
upregulation appears to be moderate and cannot be compared in magnitude to 
the classical mode of anergy induction via TCR triggered in the absence of 
costimulation.
When looking at the expression pattern of other SLFN family members we 
found to our surprise that nearly all SLFNs display upregulation at early time 
points upon activation of T lymphocytes in the presence of ct-CD45 similar to 
SLFN12 (Fig. 19). Only SLFN11 and SLFN14 do not seem to be affected by ct-
CD45 treatment at all. These results indicate that a certain degree of 
redundancy might exist within the human SLFN family which makes it difficult to 
exclude that the concerted action of SLFN family members might be required 
for the ct-CD45-induced hyporesponsive state of human T cells.
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As IL-2 could partly reverse the anergic state imposed by ct-CD45 on T cells it 
was tested whether addition of exogenous IL-2 to the culture medium alters the 
expression of SLFN12 and KLF2. Indeed, it could be shown that IL-2 strongly 
promotes the downregulation of SLFN12 mRNA in T cells treated with ct-CD45 
whereas KLF2 was only found to be altered in the absence of costimulation 
(Fig. 20). These results again suggest that SLFN12 rather than KLF2 might play 
the prominent role in this form of T cell anergy.
Fig. 27: ct-CD45-induced anergy is a non-canonical form of anergy. Impairment of cyclin 
D1 induction in T cell inhibited by ct-CD45 suggests an earlier inhibition than in canonical 
anergy which typically involves impairment of cyclin E1 expression [47]. Figure was adapted 
from [100] and modified with additional information from [47] and [53].
Although ct-CD45 has a potent action on human peripheral T cells, inhibition of 
proliferation was never observed for T cells from umbilical cord blood [77]. 
Thus, it was investigated whether SLFN12 and KLF2 are induced in these cells. 
Having determined the expression pattern again over a 24 hour time course, 
both factors were found to be expressed in cord blood T cells although the 
induction was observed to occur at a later stage than in mature T cells. SLFN12 
upregulation in ct-CD45-treated T cells was found only 12 hours post activation 
and coincided with a slight upregulation of KLF2 (Fig. 21). This was different to 
peripheral T cells where we could not find differences in KLF2 expression within 
the first 24 hours. However, unlike SLFN12, KLF2 mRNA levels never reached 
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the levels of naïve T cells. Somewhat similar to mature T cells, a slight but 
delayed induction of EGR3 mRNA was observed. Looking at the expression 
pattern of other members of the human SLFN family suggested a potential 
redundancy as SLFN5, SLFN12L and SLFN13 were induced at the very same 
time as SLFN12 (Fig. 22). The differential induction of SLFN genes for mature 
and naïve T lymphocytes provides a possible explanation for the lack of overt 
inhibition of the latter.
As Slfn1 has been implicated in the regulation of cyclin D1 expression [62] we 
also investigated the expression of G1 phase cyclins as well as of their 
respective cyclin-dependent kinases. Indeed, substantial downregulation of 
cyclin D1 in ct-CD45 treated peripheral T cells (Fig. 23) was obtained. 
Interestingly, this observation was made only after 24 hours of activation 
suggesting the need for another factor to be synthesized to enable the 
subsequent inhibition of cyclin D1. Inhibition of cyclin D2 or the E-type cyclin E1 
was not detected nor was CDK2 and CDK4 induction found to be impaired. 
Since many reports have suggested the CDK2 inhibitor p27kip1 as an anergy 
factor [47, 55] we tested its expression in our system but did not obtain any 
evidence for its involvement. As done before for SLFN gene expression cyclin 
mRNA levels were also determined in human cord blood T cells. Reduced 
expression of cyclin D1 and cyclin D2 was even detected in these cells whereas 
expression of cyclin E1 and CDKs was unaltered (Fig. 24). p27kip1 appeared to 
be slightly upregulated 24 hours after activation of cord blood T cells, but we 
lack further evidence for a major involvement of this factor. In conclusion, this 
data indicates that impairment of T cell proliferation is achieved via specific 
inhibition in the early G1 phase of the cell cycle which presumably results in 
diminished expression of IL-2 subsequently promoting the induction of anergy.
In order to prove the involvement of SLFN12 in the action of ct-CD45 siRNA-
mediated knockdown of SLFN12 was performed showing slight enhancement of 
T cell proliferation in ct-CD45-treated T cells compared to controls (Fig. 25). The 
subtle phenotype obtained requires further investigation to conclusively 
characterize SLFN12 as the major factor in the ct-CD45-induced anergic state. 
Since primary human T cells are hard to transfect a more efficient transfection 
protocol needs to be established.
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A protein associated with TLR4 (PRAT4A) had been identified as a potential 
receptor candidate by our group [77] but a physical blockade via antibodies 
could never been shown. Thus, blocking experiments were performed using a 
polyclonal antibody against PRAT4A. Preincubation with this antibody strongly 
reduced ct-CD45 binding to a PRAT4A overexpressing cell line thereby 
providing another piece of evidence for a direct interaction between these two 
molecules (Fig. 26).
Fig 28: Current model for the molecular mechanisms behind ct-CD45 generation and 
subsequent inhibition of T cell proliferation and anergy induction.
To conclude, binding of ct-CD45 to PRAT4A on activated T cells leads to the 
upregulation of SLFN12 and KLF2. The results obtained during this study 
especially demonstrate a role for SLFN12 as an anergy factor since induction of 
this factor occurs early and is impaired upon addition of exogenous IL-2. 
Furthermore, partial restorement of T cell proliferation after transfection of a 
SLFN12 siRNA provides further support for its involvement in the anergic state 
induced. 
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Regulation of cell cycle-associated factors in T cells activated in the presence of 
ct-CD45 appears to be different to canonical anergy that is characterized by a 
block in the late G1 phase [47]. The impairment of cyclin D1 mRNA induction in 
ct-CD45-challenged T cells suggests an earlier inhibition taking place already at 
the entry stage from the quiescent G0 to the G1 phase (Fig. 27). Since this 
inhibition follows SLFN12 induction it is tempting to conclude a direct effect of 
SLFN12 on cyclin D1 regulation (Fig. 28). 
Taken together, this work gives insight into the molecular mechanisms of T cell 
anergy induced via ct-CD45. The biological relevance of this state possibly lies 
in the dampening of exaggerated adaptive immune responses against 
ubiquitous but mostly harmless fungal agents. However, this mechanism might 
be exploited in immunocompromised individuals during systemic fungal 
infections where excessive generation of ct-CD45 would promote a state of 
severe immunosuppression.
Future studies will try to unravel these relations by trying to establish more 
efficient ways of SLFN12 knock-down in primary human T cells and by 
analysing the effects of SLFN12 overexpression on the activity of the cyclin D1 
promoter.
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6. Abbreviations
Abbreviation meaning
AAA ATPase family associated with various cellular activities
ACTB ?????????????-Actin)
AP-1 activator protein 1
APC antigen-presenting cell
??-m ??-microglobulin
CBL-b Casitas B cell lymphoma B
CD cluster of differentiation
CD3E ??????????????????
CDK cyclin-dependent kinase
ct-CD45 cytoplasmic tail of CD45
CTL cytotoxic T lymphocyte
CTLA-4 cytotoxic T lymphocyte-associated antigen 4
D1 / D2 domain 1 / domain 2 of CD45
DGK diacylglycerol kinase
DMSO dimethyl sulfoxide
EGR early growth response protein
ER endoplasmic reticulum
FCS fetal calf serum
FOXO forkhead box O
FOXP3 forkhead box protein 3
GAPDH glycerinaldehyde-3-phosphate dehydrogenase
GM-CSF granulocyte macrophage colony stimulating factor
GRAIL gene related to anergy in lymphocytes
GST glutathione S-transferase
HRP horseraddish peroxidase
IFN interferon
Ig immunoglobulin
I?B Inhibitor of ????
IL interleukin
KLF Krüppel-like factor
LPS lipopolysaccharide
mAb monoclonal antibody
MACS magnetic activated cell sorting
mDC monocyte-derived dendritic cell
MHC major histocompatibility complex
NFAT nuclear factor of activated T cells
Abbreviations
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???? ?????????????????
PE phycoerythrin
PRAT4A protein associated with Toll-like receptor 4
PTP protein tyrosine phosphatase
qPCR quantitative (real-time) PCR
siRNA short interfering RNA
SLFN Schlafen (family member)
SLFN12L SLFN12-like
TCR T cell receptor
TLR Toll-like receptor
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